US20120238022A1 - INDUCIBLE SYSTEMS AND METHODS FOR CONTROLLING siRNA EXPRESSION - Google Patents
INDUCIBLE SYSTEMS AND METHODS FOR CONTROLLING siRNA EXPRESSION Download PDFInfo
- Publication number
- US20120238022A1 US20120238022A1 US13/425,065 US201213425065A US2012238022A1 US 20120238022 A1 US20120238022 A1 US 20120238022A1 US 201213425065 A US201213425065 A US 201213425065A US 2012238022 A1 US2012238022 A1 US 2012238022A1
- Authority
- US
- United States
- Prior art keywords
- sirna
- promoter
- inducible
- hiv
- shrna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108020004459 Small interfering RNA Proteins 0.000 title claims abstract description 99
- 230000001939 inductive effect Effects 0.000 title claims abstract description 92
- 230000014509 gene expression Effects 0.000 title claims abstract description 80
- 238000000034 method Methods 0.000 title claims abstract description 52
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 9
- 239000004055 small Interfering RNA Substances 0.000 claims description 113
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 105
- 108090000623 proteins and genes Proteins 0.000 claims description 58
- 239000000411 inducer Substances 0.000 claims description 28
- 230000029812 viral genome replication Effects 0.000 claims description 10
- 241000700605 Viruses Species 0.000 claims description 8
- 230000010076 replication Effects 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract description 63
- 241000725303 Human immunodeficiency virus Species 0.000 abstract description 14
- 210000004027 cell Anatomy 0.000 description 128
- 101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 description 47
- 101150031823 HSP70 gene Proteins 0.000 description 46
- 101150052825 dnaK gene Proteins 0.000 description 46
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 44
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 43
- 230000009368 gene silencing by RNA Effects 0.000 description 41
- 238000013518 transcription Methods 0.000 description 33
- 230000035897 transcription Effects 0.000 description 32
- 108091030071 RNAI Proteins 0.000 description 31
- 239000013598 vector Substances 0.000 description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 239000000203 mixture Substances 0.000 description 19
- 150000007523 nucleic acids Chemical class 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 108091081021 Sense strand Proteins 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 16
- 239000000047 product Substances 0.000 description 15
- PJYYBCXMCWDUAZ-YKDQUOQBSA-N Ponasterone A Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@@](O)([C@@H](O)CCC(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 PJYYBCXMCWDUAZ-YKDQUOQBSA-N 0.000 description 14
- 102000039446 nucleic acids Human genes 0.000 description 14
- 108020004707 nucleic acids Proteins 0.000 description 14
- 230000003612 virological effect Effects 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 230000000295 complement effect Effects 0.000 description 13
- 102100031277 Calcineurin B homologous protein 1 Human genes 0.000 description 12
- 101710205625 Capsid protein p24 Proteins 0.000 description 12
- 101710177166 Phosphoprotein Proteins 0.000 description 12
- 101710149279 Small delta antigen Proteins 0.000 description 12
- 108700026226 TATA Box Proteins 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 238000001890 transfection Methods 0.000 description 12
- PJYYBCXMCWDUAZ-JJJZTNILSA-N 2,3,14,20,22-pentahydroxy-(2β,3β,5β,22R)-Cholest-7-en-6-one Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 PJYYBCXMCWDUAZ-JJJZTNILSA-N 0.000 description 11
- 102000040945 Transcription factor Human genes 0.000 description 11
- 108091023040 Transcription factor Proteins 0.000 description 11
- 230000001413 cellular effect Effects 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 238000012545 processing Methods 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 10
- 230000000692 anti-sense effect Effects 0.000 description 10
- 230000004927 fusion Effects 0.000 description 10
- -1 i.e. Proteins 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 10
- 244000052769 pathogen Species 0.000 description 10
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 9
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000011144 upstream manufacturing Methods 0.000 description 9
- 238000000636 Northern blotting Methods 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 239000012228 culture supernatant Substances 0.000 description 8
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 8
- 230000000977 initiatory effect Effects 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 230000035939 shock Effects 0.000 description 7
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 5
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 208000031886 HIV Infections Diseases 0.000 description 5
- 101710149951 Protein Tat Proteins 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000030279 gene silencing Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 108091070501 miRNA Proteins 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 238000010361 transduction Methods 0.000 description 5
- 230000026683 transduction Effects 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 230000001566 pro-viral effect Effects 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 108091006106 transcriptional activators Proteins 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 3
- 241000252212 Danio rerio Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000037357 HIV infectious disease Diseases 0.000 description 3
- 108700020121 Human Immunodeficiency Virus-1 rev Proteins 0.000 description 3
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 229930186873 Ponasterone Natural products 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 101100273253 Rhizopus niveus RNAP gene Proteins 0.000 description 3
- 102000018068 TATA-Binding Protein Associated Factors Human genes 0.000 description 3
- 108010091120 TATA-Binding Protein Associated Factors Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000012226 gene silencing method Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 208000018706 hematopoietic system disease Diseases 0.000 description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 239000002679 microRNA Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 108010069768 negative elongation factor Proteins 0.000 description 3
- 230000001613 neoplastic effect Effects 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 150000003102 ponasterones Chemical class 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
- 102000006467 TATA-Box Binding Protein Human genes 0.000 description 2
- 108010044281 TATA-Box Binding Protein Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000036436 anti-hiv Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000012761 co-transfection Methods 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000009454 functional inhibition Effects 0.000 description 2
- 238000010363 gene targeting Methods 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 108700025647 major vault Proteins 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 230000036457 multidrug resistance Effects 0.000 description 2
- 239000002088 nanocapsule Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000014723 transformation of host cell by virus Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- 101710194665 1-aminocyclopropane-1-carboxylate synthase Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010011619 6-Phytase Proteins 0.000 description 1
- WFPZSXYXPSUOPY-ROYWQJLOSA-N ADP alpha-D-glucoside Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O WFPZSXYXPSUOPY-ROYWQJLOSA-N 0.000 description 1
- WFPZSXYXPSUOPY-UHFFFAOYSA-N ADP-mannose Natural products C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COP(O)(=O)OP(O)(=O)OC1OC(CO)C(O)C(O)C1O WFPZSXYXPSUOPY-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 102100022278 Arachidonate 5-lipoxygenase-activating protein Human genes 0.000 description 1
- 101710187011 Arachidonate 5-lipoxygenase-activating protein Proteins 0.000 description 1
- 108090000433 Aurora kinases Proteins 0.000 description 1
- 102000003989 Aurora kinases Human genes 0.000 description 1
- 102100021631 B-cell lymphoma 6 protein Human genes 0.000 description 1
- 108091012583 BCL2 Proteins 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- 102000004031 Carboxy-Lyases Human genes 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010084185 Cellulases Proteins 0.000 description 1
- 102000005575 Cellulases Human genes 0.000 description 1
- 108030000630 Chalcone synthases Proteins 0.000 description 1
- 108010022172 Chitinases Proteins 0.000 description 1
- 102000012286 Chitinases Human genes 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 241001559589 Cullen Species 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 1
- 108010076010 Cystathionine beta-lyase Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108010066133 D-octopine dehydrogenase Proteins 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 208000019872 Drug Eruptions Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100035813 E3 ubiquitin-protein ligase CBL Human genes 0.000 description 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 102100034169 Eukaryotic translation initiation factor 2-alpha kinase 1 Human genes 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 102100029974 GTPase HRas Human genes 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 241001032544 Galearctus aurora Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 1
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 1
- 101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 description 1
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- 101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 description 1
- 101001012669 Homo sapiens Melanoma inhibitory activity protein 2 Proteins 0.000 description 1
- 101000973200 Homo sapiens Nuclear factor 1 C-type Proteins 0.000 description 1
- 101000573199 Homo sapiens Protein PML Proteins 0.000 description 1
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 description 1
- 101000857677 Homo sapiens Runt-related transcription factor 1 Proteins 0.000 description 1
- 101000595531 Homo sapiens Serine/threonine-protein kinase pim-1 Proteins 0.000 description 1
- 101000800488 Homo sapiens T-cell leukemia homeobox protein 1 Proteins 0.000 description 1
- 101000837626 Homo sapiens Thyroid hormone receptor alpha Proteins 0.000 description 1
- 101000813738 Homo sapiens Transcription factor ETV6 Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 102000012330 Integrases Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108700041567 MDR Genes Proteins 0.000 description 1
- 101150066553 MDR1 gene Proteins 0.000 description 1
- 108700012912 MYCN Proteins 0.000 description 1
- 101150022024 MYCN gene Proteins 0.000 description 1
- 102100029778 Melanoma inhibitory activity protein 2 Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 1
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
- 108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
- 102100022162 Nuclear factor 1 C-type Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920002730 Poly(butyl cyanoacrylate) Polymers 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 108010059820 Polygalacturonase Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100026375 Protein PML Human genes 0.000 description 1
- 102100027584 Protein c-Fos Human genes 0.000 description 1
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 108020005093 RNA Precursors Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 1
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 description 1
- 101150019443 SMAD4 gene Proteins 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 108060006706 SRC Proteins 0.000 description 1
- 241000242678 Schistosoma Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 102100036077 Serine/threonine-protein kinase pim-1 Human genes 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 108700031298 Smad4 Proteins 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010039811 Starch synthase Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
- 101000973172 Sus scrofa Nuclear factor 1 Proteins 0.000 description 1
- 102100033111 T-cell leukemia homeobox protein 1 Human genes 0.000 description 1
- 241001365914 Taira Species 0.000 description 1
- 102100028702 Thyroid hormone receptor alpha Human genes 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 102100039580 Transcription factor ETV6 Human genes 0.000 description 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 206010070517 Type 2 lepra reaction Diseases 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 102100026150 Tyrosine-protein kinase Fgr Human genes 0.000 description 1
- 102100035221 Tyrosine-protein kinase Fyn Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 108010036419 acyl-(acyl-carrier-protein)desaturase Proteins 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940025131 amylases Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000002832 anti-viral assay Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 201000004982 autoimmune uveitis Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 208000020670 canker sore Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 208000019069 chronic childhood arthritis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 108010057988 ecdysone receptor Proteins 0.000 description 1
- 150000002058 ecdysones Chemical class 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000010468 interferon response Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 108010090785 inulinase Proteins 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 108010058731 nopaline synthase Proteins 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 108020004410 pectinesterase Proteins 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000005648 plant growth regulator Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 101150098170 tat gene Proteins 0.000 description 1
- 101150065190 term gene Proteins 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000005029 transcription elongation Effects 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000003211 trypan blue cell staining Methods 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000006490 viral transcription Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
Definitions
- the present invention relates to RNA interference.
- the invention relates to an inducible system and methods for controlling the expression of siRNA and to use of the system for inhibiting gene expression.
- RNAi RNA interference
- the proteins mediating RNA interference (RNAi) are part of an evolutionarily conserved cellular pathway that processes endogenous cellular RNAs to silence developmentally important genes (Grishok et al., 2001; Hutvagner et al., 2001).
- RNAi is a potent inhibitor of targeted gene expression in a wide variety of organisms (Wianny and Zernica-Goetz, 2000; Kennerdell and Carthew, 1998; Fire et al., 1998).
- RNAi small interfering RNAs
- siRNAs small interfering RNAs
- RNAi mediated gene silencing in mammalian cells has been achieved by either transfecting synthetic dsRNA (Caplan et al., 2001; Elbashir et al., 2001), plasmids (Brummelkamp et al., 2002; Lee et al., 2002; Miyagishi and Taira, 2002) expressing siRNA as individual sense and antisense strands, or the use of short hairpin RNAs (shRNAs) 21-29 nucleotides long which are processed by the RNAse III family member Dicer to siRNA sized molecules that guide the cleavage of cognate mRNA (Xia et al., 2002; An et al., 2003).
- shRNAs short hairpin RNAs
- a Pol II promoter could also be used to express shRNAs (Xia et al., 2002). Some of the restrictions for expression of a functional shRNA include elimination of non-base paired 5′ sequences and the use of a minimal poly A signal (Xia et al., 2002). There are several potential advantages to utilizing Pol II expressed shRNAs including tissue specific promoters and inducible transcription. Given the requirement for a poly A signal at the 3′ end of the transcriptional units, it is not known how the final shRNAs are produced, and which transport system is used to export these to the cytoplasm. Nevertheless, it is clear that functional siRNAs can be produced by Pol II systems.
- siRNAs Small interfering RNAs
- siRNAs can induce potent gene silencing by directing degradation of cognate mRNAs. Controlled expression of siRNA may be important in clinical settings because it has been reported that some siRNA and shRNA sequences can induce a non-specific interferon response.
- the present invention thus provides controlled expression of siRNA.
- the present invention relates to an inducible system for controlling expression of siRNA, including short hairpin RNA (shRNA).
- the inducible system comprises a suitable promoter operatively associated with an inducible element.
- siRNA is preferably produced only in the presence of an inducer which is specific for the inducible element.
- the invention is useful for inhibiting gene expression.
- the present invention provides an inducible fusion promoter for expressing siRNA or shRNA.
- the inducible fusion promoter comprises a suitable promoter operatively associated with an inducible element.
- the inducible element is responsive to a tissue specific, viral specific, cellular specific or engineered transcription factor.
- the inducible element is responsive to a viral specific transcription factor.
- the virus is HIV.
- the inducer is TAT.
- the inducible element is the HIV-1 LTR containing the TAR sequences.
- the present invention provides for the inducible expression of siRNA (shRNA) in response to an inducer through the use of the inducible fusion promoter to which the siRNA (shRNA) is operably linked.
- the fusion promoter should express siRNA (shRNA) only in cells that express the inducer.
- the cells naturally express the inducer.
- the cells are viral infected cells that express the inducer.
- the cells are cells transfected with a vector that expresses the inducer.
- the cells are cells harboring HIV-1.
- the cells are cells transfected with a vector expressing the TAT gene.
- the present invention provides pharmaceutical compositions containing the inducible siRNA (shRNA).
- shRNA inducible siRNA
- the present invention provides methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene.
- the method involves introducing into the environment of a cell an amount of a inducible siRNA (shRNA) such that a sufficient portion of the siRNA (shRNA) can be induced in the cell to cause a reduction in the expression of the target gene.
- shRNA inducible siRNA
- siRNA expression according to the present invention translates to an efficient inhibition of gene expression in a transient as well as in a stable long-term setting.
- FIG. 1A shows an shRNA sequence and expression cassettes.
- an shRNA sequence SEQ ID NO:1 with minimal polyadenylation signal sequence is shown.
- One of the boxes shows the position of the G-U wobble pairing.
- FIG. 1B are photographs showing inhibition of RevEGFP expression by shRNAs.
- EcR-293 cells were co-transfected with pIND-RevEGFP and shRNA constructs in the presence and absence of ponasterone, as indicated. Cells were examined microscopically for EGFP expression as described in the Examples. The right panels in all cases are phase contrast images taken at the time of fluorescent microscope analysis (left panels) showing that approximately equivalent numbers of cells are present in each field. Cells transfected with shRNA construct without the leader element removed showed an approximate 90% reduction in fluorescent cells. Cells transfected with pIND-shRNA showed EGFP expression levels similar to that observed with cells transfected with only the Rev-EGFP construct. Specific silencing of Rev-EGFP was confirmed by at least three independent experiments.
- FIG. 1C shows results of a Northern blot analysis of EcR-293 cells transfected with shRNA constructs in the presence and absence of ponasterone, as indicated.
- mpIND-shRNAmpolyA construct showed expression and processing to siRNA-sized products, both in the presence and absence of the inducer while the construct with the leader element showed no processing even in the presence of the inducer.
- Upper arrow indicates primary transcript region, the lower bands indicate partially processed hairpin and siRNAs, respectively.
- the strong band in all lanes is an unknown cellular transcript that has homology to the oligonucleotide probe.
- M Marker (21 nucleotide RNA).
- FIG. 1D is a graph showing inhibition of HIV-1 gene expression by shRNA constructs.
- EcR-293 cells were co-transfected with wild type infectious proviral DNA, pNL4-3 and mpIND-shRNAmpolyA in the presence and absence of ponasterone, as indicated. Inhibition is seen both in the presence and absence of the inducer.
- FIG. 1E shows results of a Northern blot analysis of total RNA extracted from the above cells and shows that siRNA expression and processing occurs both in the presence and absence of the inducer.
- the arrows indicate partially processed and fully processed shRNAs and siRNAs, respectively.
- the strong band in all lanes is a cellular transcript that has homology to the oligonucleotide probe.
- FIG. 2A shows a schematic representation of LTRhsp-shRNA. HIV-1 LTR along with the TAR loop region was cloned upstream of the minimal hsp70 promoter.
- FIG. 2B shows results of a Northern blot analysis of 293 cells and shows Tat inducible expression of shRNAs.
- Cells were co-transfected with LTRhsp-shRNA or the hsp70 TATA mutated construct in the presence or absence of a Tat expressing plasmid, as indicated. Expression and processing to siRNA-sized products was only observed in the presence of Tat. The hsp70 TATA mutated construct did not show any processing.
- mpIND-shRNAmpolyA was transfected as a Pol II expressed shRNA control. Arrows indicate partially processed precursor and siRNA sized products. The strong band common to all lanes is an endogenous sequence with homology to the antisense olignucleotide probe.
- FIG. 2C is a graph showing Inhibition of HIV gene expression by LTRhsp-shRNA. 293 cells were co-transfected with pNL4-3 and fold decrease in HIV-1 p24 is observed in cells transfected with LTRhsp-shRNA. The level of inhibition was comparable to that observed with mpIND-shRNAmpolyA which was used as Pol II expressed shRNA control.
- FIG. 2D shows results of a Northern blot analysis of total RNA extracted from the above cells and shows efficient expression and processing in cells transfected with LTRhsp-shRNA and mpIND-shRNAmpolyA. The siRNA sized products are indicated, the band above these is the partially processed shRNA.
- FIG. 3A shows a schematic representation of a packaging system useful for inhibition of HIV-1 replication.
- the lentiviral vector, pHIV-7-GFP contains a hybrid 5′ LTR in which the U3 region is replaced with the CMV promoter, the packaging signal ( ⁇ ), the RRE sequence, the EGFP gene driven by CMV promoter, and the 3′ LTR in which the cis regulatory sequences are completely removed from the U3 region.
- LTRhsp-shRNA mpolyA is inserted directly upstream of the CMV promoter of EGFP in pHIV-7-GFP vector in the reverse orientation.
- the solid box between RRE and CMV-EGFP represents the FLAP sequence of HIV-1.
- pCHGP-2 contains the gag and pol genes and RRE sequence from HIV-1 under the control of the CMV promoter.
- pCMV-Rev contains the coding sequence of Rev driven by the CMV promoter.
- pCMV-G contains the VSV-G protein gene under the control of the CMV promoter.
- pA indicates the polyadenylation signal from the human ⁇ -globin gene.
- FIGS. 3B and 3C show the results of an HIV-1 challenge assay.
- CD34 stem cells or CEM cells transduced with pHIV-7-LTRhspshRNA were challenged with a JRFL or HIV-1 IIIB strain, respectively.
- Culture supernatants were collected and p24 ELISA was carried out as described in the Examples.
- LTRshREV LTRhsp-shRNA cloned in the reverse orientation.
- FIG. 4 is a gel photograph showing transcription occurring from both HIV-1 LTR and mhsp70 TATA boxes. 293 cells were co-transfected with pNL4-3 and LTRhsp-shRNA or hsp70 TATA mutant. 50 ngs of Total RNA was used for RT-PCR analysis using primers flanking the HIV-1 TAR and hsp70 TATA box sequences. Lanes corresponding to the LTRhsp-shRNA and the hsp70 TATA mutant showed signals of similar intensity. GAPDH was amplified as an internal control.
- FIGS. 5A and 5B show partial processing of an shRNA loop.
- FIG. 5A the results of a Northern blot analysis are shown in which total RNA is extracted from 293 cells co-transfected with shRNA constructs and pNL4-3. A strong 39 base partially processed form can be observed when the blot was probed to detect the antisense strand. This product was observed when the blot was probed to detect the antisense strand. This product was not detectable when a probe complementary to the sense strand was used. The upper band is the partially processed shRNA and the lower band is the fully processed siRNA.
- FIG. 5B is a schematic depiction of shRNA processing.
- An shRNA that is processed fully from the 3′ end should result in three molecular species, a partially processed hairpin with the loop processed at the 5′ end of the antisense strand, a fully processed loop and a partially processed species with the loop processed at the 3′ end of the sense strand of size ca 39 bases.
- FIG. 6 is a schematic representation of a general inducible system using a fusion promoter according to the invention.
- the cis-acting regulatory elements are cloned either between the TAR loop and the minimal hsp70 promoter, as shown, or downstream of the minimal polyadenylation signal sequence (mpolyA). Transcription of the TAR loop by the HIV-1 LTR recruits N-TEF components NELF (tetramer) and DSIF (dimer). These in turn suppress transcription from the hsp70 promoter as well as HIV-1 LTR. Binding of cis-acting transcriptional activators either downstream of the minimal polyA or between the TAR loop and the minimal hsp70 promoter activates shRNA transcription from the hsp70 promoter.
- the present invention relates to an inducible system for controlling expression of siRNA, including short hairpin RNA (shRNA).
- the inducible system comprises a nucleic acid construct that comprises a suitable promoter operatively associated with an inducible element.
- the nucleic acid construct may also further comprise siRNA (shRNA) operably associated with the promoter.
- shRNA siRNA
- the siRNA is preferably produced only in the presence of an inducer which is specific for the inducible element.
- the invention is useful for inhibiting gene expression.
- nucleic acid construct refers to an isolated polynucleotide which is introduced into a host cell.
- This construct may comprise any combination of deoxyribonucleotides, ribonucleotides, and/or modified nucleotides.
- the construct may be transcribed to form an RNA, wherein the RNA may be capable of forming a double-stranded RNA and/or hairpin structure.
- This construct may be expressed in the cell, or isolated or synthetically produced.
- the construct may further comprise a promoter, or other sequences which facilitate manipulation or expression of the construct.
- the present invention provides an inducible fusion promoter for expressing siRNA or shRNA.
- the inducible fusion promoter is a nucleic acid construct that comprises a suitable promoter operatively associated with an inducible element.
- the inducible element is responsive to an inducer.
- the inducer is a tissue specific transcription factor, a viral specific transcription factor, a cellular specific transcription factor or an engineered transcription factor.
- the inducible element is responsive to a viral specific transcription factor.
- the virus is HIV.
- the inducer is TAT.
- the inducible element is the HIV-1 LTR containing the TAR sequences.
- operably linked or “operably associated” includes reference to a functional linkage of at least two sequences.
- operably linked includes linkage between a promoter and a second sequence, wherein the promoter sequence initiates and mediates transcription of the DNA sequence corresponding to the second sequence.
- Operably associated includes linkage between an inducing element and a promoter, wherein the inducing element acts as a transcriptional activator of the promoter.
- promoter includes reference to a region of DNA that is involved in recognition and binding of an RNA polymerase and other proteins to initiate transcription.
- the promoter is a Pol II promoter. Any Pol II promoter may be used in accordance with the present invention.
- the Pol II promoter is a heat shock promoter.
- the heat shock promoter is a minimal heat shock promoter.
- the minimal heat shock promoter is the Drosophila hsp70 minimal heat shock promoter.
- an “inducible element” includes an element that confers regulation on transcription of a downstream expressed region under inducing conditions. It may be obtained from enhancer regions that are also inducible. Removal of an inducible element from the downstream expressed region would be expected to decrease expression of a downstream region under inducing conditions.
- Inducible elements e.g., consensus sequences known in the art are usually between about 4 and 100 nucleotides in length.
- the inducible element is HIV-1 TAR (transactivation-responsive region).
- TAR resides within the R region of the HIV-1 long terminal repeat (LTR), between ⁇ 17 and +54 with respect to the initiation site of viral transcription (Feng and Holland, 1988; Rosen et al., 1985; Muesing et al., 1987).
- LTR long terminal repeat
- the RNA encoded between +1 and +59 has the potential to from an extensive stem-loop secondary structure which, as a portion of the untranslated leader RNA, would be common to all HIV-1 mRNAs (Muesing et al., 1987; Okamoto and Wong-Staal, 1986). Studies have shown that the sequence +30 CUGGG +34 in TAR within the loop of the hairpin structure is required for TAT transactivation (Feng and Holland, 1988).
- encodes or “encoding” refers to a DNA sequence which can be processed to generate an RNA and/or polypeptide.
- inducer includes an agent that induces, especially a substance that is capable of activating transcription from specific genes within a cell.
- the inducer is HIV-1 TAT (trans-activator of transcription).
- HIV-1 TAT is a 14 kDa viral protein involved in the regulation of HIV-1 transcriptional elongation (Kao et al., 1987; Feinberg et al., 1991; Marciniak and Sharp, 1991) and in its presence, viral replication increases by greater than 100-fold (Cullen, 1986; Muesing et al., 1987). It functions to trigger efficient RNA chain elongation by binding to TAR RNA, which forms the initial portion of the HIV-1 transcript (Berkhout et al., 1989).
- the interaction between TAT and TAR is critical for virus replication and mutations in TAT that alter the RNA-binding site result in defective viruses.
- virus replication can be strongly inhibited by the overexpression of TAR RNA sequences that act as competitive inhibitors of regulatory protein binding (Graham and Maio, 1990).
- the present invention relates to an HIV inducible shRNA system, preferably containing a suitable promoter operably associated with an inducible element that is inducible by HIV TAT.
- part of a TATA box region such as the Drosophila hsp70 TATA box region, is cloned downstream of the HIV-1 LTR containing the TAR region.
- an anti-HIV shRNA expressed from a Pol II promoter was demonstrated to inhibit HIV-1 gene expression in mammalian cells.
- This preferred strategy was applied to design a novel promoter system where, in a preferred embodiment, the HIV-1 LTR is fused to the Drosophila hsp70 minimal heat shock promoter. This system is inducible by HIV-1 TAT, providing regulated expression of the shRNA.
- an inducible system comprises a suitable promoter operatively associated with an HIV TAR region, which instead of acting as a transcriptional activator by recruiting TAT, acts as a repressor by recruiting, for example, N-TEF, thereby suppressing transcription from the promoter.
- siRNA siRNA
- expression then can be induced in response to inducing elements (e.g., transcription factors) associating with inducible elements (e.g., regulatory elements), which also can be operatively associated with the promoter.
- a nucleic acid construct is provided to encode the siRNA (shRNA) for any specific target sequence.
- siRNA siRNA
- Any siRNA (shRNA) can be inserted into the construct containing the inducible system, such that the encoded siRNA (shRNA) selectively targets and suppresses the target sequence.
- a cell containing a nucleic acid construct of the present invention is also provided.
- host cell is meant a cell which contains an introduced nucleic acid construct and supports the replication and/or expression of the construct.
- the cell is a cell that naturally contains the inducer.
- the cell is one that is infected by HIV-1, and thus produces TAT.
- cells infected with HIV-1 can efficiently induce siRNA (shRNA) expression from a construct according to the present invention.
- the cell is one that is transfected with a nucleic acid construct comprising a TAT coding sequence operably linked to a promoter, such that TAT is produced in the cell.
- the promoter associated with the TAT encoding nucleic acid sequence may be any promoter, such as a constitutive promoter, a tissue-preferred promoter, an inducible promoter or a derepressible promoter.
- introducing encompasses a variety of methods of introducing DNA into a cell, either in vitro or in vivo, such methods including transformation, transduction, transfection, and infection.
- Vectors are useful and preferred agents for introducing DNA encoding the interfering RNA molecules into cells.
- Possible vectors include plasmid vectors and viral vectors.
- Viral vectors include retroviral vectors, lentiviral vectors, or other vectors such as adenoviral vectors or adeno-associated vectors.
- a method for suppressing a target sequence employs the constructs above, in which a siRNA (shRNA) is designed to a region of the target sequence, and inserted into the construct. Upon introduction into a cell and upon induction of the inducible system, the siRNA (shRNA) produced suppresses expression of the targeted sequence.
- the cell is one that is infected with HIV-1, and the invention provides a method of inhibiting viral replication, thus establishing a negative feedback loop.
- the cell is one that is transfected with a nucleic acid construct comprising a nucleic acid sequence encoding TAT, and the invention provides a method of inhibiting any target sequence.
- Transformation protocols as well as protocols for introducing nucleotide sequences into cells may vary depending on the type of cell targeted for transformation. Suitable methods of introducing the DNA construct into cells are well known in the art and include microinjection, electroporation, direct gene transfer, ballistic particle transformation, viral transformation, retroviral transformation and the like.
- transient expression may be desired.
- standard transient transformation techniques may be used. Such methods include, but are not limited to viral transformation methods, and microinjection of DNA or RNA, as well other methods well known in the art.
- Initial identification and selection of cells and/or plants comprising the DNA constructs may be facilitated by the use of marker genes.
- Gene targeting can be performed without selection if there is a sensitive method for identifying recombinants, for example if the targeted gene modification can be easily detected by PCR analysis, or if it results in a certain phenotype. However, in most cases, identification of gene targeting events will be facilitated by the use of markers.
- Useful markers include positive and negative selectable markers as well as markers that facilitate screening, such as visual markers.
- the RNAi, and preferably siRNA, or shRNA, molecules are double-stranded (ds) RNAs, i.e., RNAs that contain a duplex region, that preferably contain about 19 to 23, or 21 to 29, base pairs, respectively.
- the molecules also preferably contain 3′ overhangs, more preferably 3′UU or 3′TT overhangs.
- Each strand of the double stranded nucleic acid may comprise RNA, RNA analog(s) or RNA and DNA.
- the antisense strand of the siRNA is sufficiently complementary with the target sequence of the target gene.
- siRNA and shRNA constructs are designed and prepared using techniques well known in the art, including those described in copending application Ser. No. 11/079,906 filed on 15 Mar. 2005, incorporated herein by reference.
- the siRNA or shRNA is operably associated with the inducible fusion promoter of the present invention.
- duplex region refers to the region in two complementary or substantially complementary oligonucleotides that form base pairs with one another, either by Watson-Crick base pairing or any other manner that allows for a duplex between oligonucleotide strands that are complementary or substantially complementary.
- an oligonucleotide strand having 21 nucleotide units can base pair with another oligonucleotide of 21 nucleotide units, yet only 19 bases on each strand are complementary or substantially complementary, such that the “duplex region” consists of 19 base pairs.
- the remaining base pairs may, for example, exist as 5′ and 3′ overhangs.
- nucleic acid sequence a sequence of strands such that they are capable of annealing under biological conditions.
- Techniques to empirically determine if two strands are capable of annealing under biological conditions are well know in the art.
- two strands can be synthesized and added together under biological conditions to determine if they anneal to one another.
- RNAi methods are applicable to a wide variety of genes in a wide variety of organisms and the disclosed compositions and methods can be utilized in each of these contexts.
- genes which can be targeted by the disclosed compositions and methods include endogenous genes which are genes that are native to the cell or to genes that are not normally native to the cell. Without limitation these genes include oncogenes, cytokine genes, idiotype (Id) protein genes, prion genes, genes that expresses molecules that induce angiogenesis, genes for adhesion molecules, cell surface receptors, proteins involved in metastasis, proteases, apoptosis genes, cell cycle control genes, genes that express EGF and the EGF receptor, multi-drug resistance genes, such as the MDR1 gene.
- Target sequence is used to mean the nucleic acid sequence that is selected for suppression of expression, and is not limited to polynucleotides encoding polypeptides.
- the target sequence comprises a sequence that is substantially or completely complementary to the miRNA.
- the target sequence can be RNA or DNA, and may also refer to a polynucleotide comprising the target sequence.
- nucleic acid means a polynucleotide and includes single or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases. Nucleic acids may also include fragments and modified nucleotides.
- vector includes reference to a nucleic acid used in introduction of a polynucleotide of the invention into a host cell. Expression vectors permit transcription of a nucleic acid inserted therein.
- the target mRNA of the invention specifies the amino acid sequence of a cellular protein (e.g., a nuclear, cytoplasmic, transmembrane, or membrane-associated protein).
- the target mRNA of the invention specifies the amino acid sequence of an extracellular protein (e.g., an extracellular matrix protein or secreted protein).
- the phrase “specifies the amino acid sequence” of a protein means that the mRNA sequence is translated into the amino acid sequence according to the rules of the genetic code.
- developmental proteins e.g., adhesion molecules, cyclin kinase inhibitors, Wnt family members, Pax family members, Winged helix family members, Hox family members, cytokines/lymphokines and their receptors, growth/differentiation factors and their receptors, neurotransmitters and their receptors
- oncogene-encoded proteins e.g., ABLI, BCLI, BCL2, BCL6, CBFA2, CBL, CSFIR, ERBA, ERBB, EBRB2, ETSI, ETSI, ETV6, FGR, FOS, FYN, HCR, HRAS, JUN, KRAS, LCK, LYN, MDM2, MLL, MYB, MYC, MYCLI, MYCN, NRAS, PIM I, PML, RET, SRC, TALI, TCL3, and YES); tumor suppressor proteins (e.g., APC, BRCA1,
- the target mRNA molecule of the invention specifies the amino acid sequence of a protein associated with a pathological condition.
- the protein may be a pathogen-associated protein (e.g., a viral protein involved in immunosuppression of the host, replication of the pathogen, transmission of the pathogen, or maintenance of the infection), or a host protein which facilitates entry of the pathogen into the host, drug metabolism by the pathogen or host, replication or integration of the pathogen's genome, establishment or spread of infection in the host, or assembly of the next generation of pathogen.
- a pathogen-associated protein e.g., a viral protein involved in immunosuppression of the host, replication of the pathogen, transmission of the pathogen, or maintenance of the infection
- a host protein which facilitates entry of the pathogen into the host, drug metabolism by the pathogen or host, replication or integration of the pathogen's genome, establishment or spread of infection in the host, or assembly of the next generation of pathogen.
- Pathogens include RNA viruses such as flaviviruses, picornaviruses, rhabdoviruses, filoviruses, retroviruses, including lentiviruses, or DNA viruses such as adenoviruses, poxviruses, herpes viruses, cytomegaloviruses, hepadnaviruses or others. Additional pathogens include bacteria, fungi, helminths, schistosomes and trypanosomes. Other kinds of pathogens can include mammalian transposable elements. Alternatively, the protein may be a tumor-associated protein or an autoimmune disease-associated protein.
- the target gene may be derived from or contained in any organism.
- the organism may be a plant, animal, protozoa, bacterium, virus or fungus. See e.g., U.S. Pat. No. 6,506,559, incorporated herein by reference.
- the present invention provides for a pharmaceutical composition comprising the dsRNA of the present invention.
- the dsRNA sample can be suitably formulated and introduced into the environment of the cell by any means that allows for a sufficient portion of the sample to enter the cell to induce gene silencing, if it is to occur.
- Many formulations for dsRNA are known in the art and can be used so long as dsRNA gains entry to the target cells so that it can act. See, e.g., U.S. published patent application Nos. 2004/0203145 A1 and 2005/0054598 A1, each incorporated herein by reference.
- dsRNA can be formulated in buffer solutions such as phosphate buffered saline solutions, liposomes, micellar structures, and capsids.
- buffer solutions such as phosphate buffered saline solutions, liposomes, micellar structures, and capsids.
- Formulations of dsRNA with cationic lipids can be used to facilitate transfection of the dsRNA into cells.
- cationic lipids such as lipofectin (U.S. Pat. No. 5,705,188, incorporated herein by reference), cationic glycerol derivatives, and polycationic molecules, such as polylysine (published PCT International Application WO 97/30731, incorporated herein by reference), can be used.
- Suitable lipids include Oligofectamine, Lipofectamine (Life Technologies), NC388 (Ribozyme Pharmaceuticals, Inc., Boulder, Colo.), or FuGene 6 (Roche) all of which can be used according to the manufacturer's instructions.
- the method of introducing dsRNA into the environment of the cell will depend on the type of cell and the make up of its environment.
- a lipid formulation such as in lipofectamine and the dsRNA can be added directly to the liquid environment of the cells.
- Lipid formulations can also be administered to animals such as by intravenous, intramuscular, or intraperitoneal injection, or orally or by inhalation or other methods as are known in the art.
- the formulation is suitable for administration into animals such as mammals and more specifically humans, the formulation is also pharmaceutically acceptable.
- Pharmaceutically acceptable formulations for administering oligonucleotides are known and can be used.
- dsRNA in a buffer or saline solution and directly inject the formulated dsRNA into cells, as in studies with oocytes.
- the direct injection of dsRNA duplexes may also be done.
- suitable methods of introducing dsRNA see U.S. published patent application No. 2004/0203145 A1, incorporated herein by reference.
- dsRNA Suitable amounts of dsRNA must be introduced and these amounts can be empirically determined using standard methods. Typically, effective concentrations of individual dsRNA species in the environment of a cell will be about 50 nanomolar or less 10 nanomolar or less, or compositions in which concentrations of about 1 nanomolar or less can be used. In other embodiment, methods utilize a concentration of about 200 picomolar or less and even a concentration of about 50 picomolar or less can be used in many circumstances.
- the method can be carried out by addition of the dsRNA compositions to any extracellular matrix in which cells can live provided that the dsRNA composition is formulated so that a sufficient amount of the dsRNA can enter the cell to exert its effect.
- the method is amenable for use with cells present in a liquid such as a liquid culture or cell growth media, in tissue explants, or in whole organisms, including animals, such as mammals and especially humans.
- the dsRNA can be formulated as a pharmaceutical composition which comprises a pharmacologically effective amount of a dsRNA and pharmaceutically acceptable carrier.
- a pharmacologically or therapeutically effective amount refers to that amount of a dsRNA effective to produce the intended pharmacological, therapeutic or preventive result.
- the phrases “pharmacologically effective amount” and “therapeutically effective amount” or simply “effective amount” refer to that amount of an RNA effective to produce the intended pharmacological, therapeutic or preventive result.
- a therapeutically effective amount of a drug for the treatment of that disease or disorder is the amount necessary to effect at least a 20% reduction in that parameter.
- pharmaceutically acceptable carrier refers to a carrier for the administration of a therapeutic agent.
- exemplary carriers include saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof.
- pharmaceutically acceptable carriers include, but are not limited to pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservatives.
- suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, while corn starch and alginic acid are suitable disintegrating agents.
- Binding agents may include starch and gelatin, while the lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract.
- the pharmaceutically acceptable carrier of the disclosed dsRNA composition may be micellar structures, such as a liposomes, capsids, capsoids, polymeric nanocapsules, or polymeric microcapsules.
- compositions of this invention can be administered by any means known in the art such as by parenteral routes, including intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, airway (aerosol), rectal, vaginal and topical (including buccal and sublingual) administration.
- parenteral routes including intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, airway (aerosol), rectal, vaginal and topical (including buccal and sublingual) administration.
- parenteral routes including intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, airway (aerosol), rectal, vaginal and topical (including buccal and sublingual) administration.
- parenteral routes including intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, airway (aerosol), rectal, vaginal and topical (including buccal and sublingual) administration.
- the pharmaceutical compositions are administered by intravenous or intraparenteral infusion or injection
- a suitable dosage unit of dsRNA will be in the range of 0.001 to 0.25 milligrams per kilogram body weight of the recipient per day, or in the range of 0.01 to 20 micrograms per kilogram body weight per day, or in the range of 0.01 to 10 micrograms per kilogram body weight per day, or in the range of 0.10 to 5 micrograms per kilogram body weight per day, or in the range of 0.1 to 2.5 micrograms per kilogram body weight per day.
- Pharmaceutical composition comprising the dsRNA can be administered once daily. However, the therapeutic agent may also be dosed in dosage units containing two, three, four, five, six or more sub-doses administered at appropriate intervals throughout the day.
- the dsRNA contained in each sub-dose must be correspondingly smaller in order to achieve the total daily dosage unit.
- the dosage unit can also be compounded for a single dose over several days, e.g., using a conventional sustained release formulation which provides sustained and consistent release of the dsRNA over a several day period. Sustained release formulations are well known in the art.
- the dosage unit contains a corresponding multiple of the daily dose.
- the pharmaceutical composition must contain dsRNA in a quantity sufficient to inhibit expression of the target gene in the animal or human being treated.
- the composition can be compounded in such a way that the sum of the multiple units of dsRNA together contain a sufficient dose.
- Data can be obtained from cell culture assays and animal studies to formulate a suitable dosage range for humans.
- the dosage of compositions of the invention lies within a range of circulating concentrations that include the ED 50 (as determined by known methods) with little or no toxicity.
- the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
- the therapeutically effective dose can be estimated initially from cell culture assays.
- a dose may be formulated in animal models to achieve a circulating plasma concentration range of the compound that includes the IC 50 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture.
- IC 50 concentration of the test compound which achieves a half-maximal inhibition of symptoms
- levels of dsRNA in plasma may be measured by standard methods, for example, by high performance liquid chromatography.
- the present invention relates to a method for treating a subject having a disease or at risk of developing a disease caused by the expression of a target gene.
- the dsRNA can act as novel therapeutic agents for controlling one or more of cellular proliferative and/or differentiative disorders, disorders associated with bone metabolism, immune disorders, hematopoietic disorders, cardiovascular disorders, liver disorders, viral diseases, or metabolic disorders.
- the method comprises administering a pharmaceutical composition of the invention to the patient (e.g., human), such that expression of the target gene is silenced. Because of their high specificity, the dsRNAs of the present invention specifically target mRNAs of target genes of diseased cells and tissues.
- the target gene may be one which is required for initiation or maintenance of the disease, or which has been identified as being associated with a higher risk of contracting the disease.
- the dsRNA can be brought into contact with the cells or tissue exhibiting the disease.
- dsRNA substantially identical to all or part of a mutated gene associated with cancer, or one expressed at high levels in tumor cells, e.g. aurora kinase may be brought into contact with or introduced into a cancerous cell or tumor gene.
- Examples of cellular proliferative and/or differentiative disorders include cancer, e.g., carcinoma, sarcoma, metastatic disorders or hematopoietic neoplastic disorders, e.g., leukemias.
- a metastatic tumor can arise from a multitude of primary tumor types, including but not limited to those of prostate, colon, lung, breast and liver origin.
- cancer e.g., carcinoma, sarcoma
- metastatic disorders or hematopoietic neoplastic disorders e.g., leukemias.
- a metastatic tumor can arise from a multitude of primary tumor types, including but not limited to those of prostate, colon, lung, breast and liver origin.
- the terms “cancer,” “hyperproliferative,” and “neoplastic” refer to cells having the capacity for autonomous growth, i.e., an abnormal state of condition characterized by rapidly proliferating cell growth.
- Proliferative disorders also include hematopoietic neoplastic disorders, including diseases involving hyperplastic/neoplatic cells of hematopoictic origin, e.g., arising from myeloid, lymphoid or erythroid lineages, or precursor cells thereof.
- the present invention can also be used to treat a variety of immune disorders, in particular those associated with overexpression of a gene or expression of a mutant gene.
- hematopoietic disorders or diseases include, without limitation, autoimmune diseases (including, for example, diabetes mellitus, arthritis (including rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis), multiple sclerosis, encephalomyelitis, myasthenia gravis, systemic lupus erythematosis, automimmune thyroiditis, dermatitis (including atopic dermatitis and eczematous dermatitis), psoriasis, Sjogren's Syndrome, Crohn's disease, aphthous ulcer, ulceris, conjunctivitis, keratoconjunctivitis, ulcerative colitis, asthma, allergic asthma, cutaneous lupus erythematosus, scleroderma, va
- the invention in another embodiment, relates to a method for treating viral diseases, including but not limited to human papilloma virus, hepatitis C, hepatitis B, herpes simplex virus (HSV), HIV-AIDS, poliovirus, and smallpox virus.
- dsRNAs of the invention are prepared as described herein to target expressed sequences of a virus, thus ameliorating viral activity and replication.
- the molecules can be used in the treatment and/or diagnosis of viral infected tissue, both animal and plant. Also, such molecules can be used in the treatment of virus-associated carcinoma, such as hepatocellular cancer.
- MDR multi-drug resistance 1 gene
- MDR1 multi-drug resistance 1 gene
- Pgp P-glycoprotein
- MDR-associated protein MDR-associated protein
- LRP lung resistance protein
- the practice of the present invention employs, unless otherwise indicated, conventional techniques of chemistry, molecular biology, microbiology, recombinant DNA, genetics, immunology, cell biology, cell culture and transgenic biology, which are within the skill of the art. See, e.g., Maniatis et al., 1982 , Molecular Cloning (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.); Sambrook et al., 1989 , Molecular Cloning, 2nd Ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.); Sambrook and Russell, 2001 , Molecular Cloning, 3rd Ed.
- the siRNA was designed to target a highly accessible site in the HIV-1 rev transcript as previously reported (Lee et al., 2002).
- the shRNA design involved extending the sense strand by eight nucleotides on the 3′ end to obtain a 28-nucleotide stem.
- a single C to U point mutation was designed in the center of the sense strand to facilitate cloning.
- the sequence of the 9 base loop was described previously by Xia et al. (2002).
- the pIND promoter was amplified by PCR using primers that would amplify the promoter alone, or the promoter plus the 5′ leader sequence from the pIND vector (Invitrogen).
- PCR products from both of the above reactions were blunt end ligated to one another and cloned in the pCR2.1 vector (Invitrogen).
- the construct without the leader element was designated as mpIND-shRNAmpolyA and the construct with the leader element was called pIND-shRNAmpolyA.
- the E/GRE elements were removed from the mpIND-shRNAmpolyA construct using Bgl II and Xma I and the pNL4-3 derived HIV-1 LTR was inserted in the same position ( FIG. 2A ).
- the hsp70 TATA mutant construct was obtained by mutating the hsp70 TATA box to a Cla I site.
- pHIV-7 Construction and characteristics of the lentiviral vector pHIV-7 have been previously described (Gasmi et al., 1999).
- pHIV-LTRhsp-shRNA the entire LTRhsp-shRNA along with the minimal polyA signal sequence was PCR amplified and cloned in Not I and BstE II sites of pHIV-7 in the reverse orientation.
- ECR-293 cells were obtained from Invitrogen and maintained according to the supplier's instructions.
- HT1080 and 293 Cells were maintained in DMEM 20% FBS. Twenty-four hours before transfection, cells were replated in 6-well plates at 50-70% confluency with fresh medium without antibiotics.
- the Human T cell Line CEM was maintained in RPMI1640 medium supplemented with 10% FBS.
- the target either pIND RevEGFP or pNL4-3
- 293T cells were cultured until they reached 80% confluency in a 100 mm culture dish.
- 15 ng of lentiviral vector with the appropriate insert, 15 ⁇ g of pCHGP-2, 5 ⁇ g of pCMV-G and 5 ⁇ g of pCMV-Rev were cotransfected into 293T cells using the calcium phosphate precipitation procedure (Graham and van der Eb, 1973).
- the packaging system is shown in FIG. 3A (Gasmi et al., 1999). Six hours after transfection, the culture medium was replaced. The culture supernatants were collected at 24 h and 36 h after transfection.
- the supernatants were pooled together, passed through a 0.45 nm filter, concentrated by ultracentrifugation, and stored at ⁇ 80° C. until use.
- Vector titers were determined by transduction of HT1080 cells and assayed for EGFP expression using flow cytometry.
- the vectors were free of replication competent lentivirus as determined by both RT-PCR and p24 antigen assays.
- CD34+ stem cells were enriched from umbilical cord blood by anti-CD34+ antibody-coupled magnetic beads (Miltenyi Biotech, Aubum, Calif.). The purity of CD34+ cells was above 90% as determined by FACS analysis.
- IMDM Iscove's modified Dulbecco's medium
- CEM-T cells Twenty-four hours after transduction, 1 ⁇ 10 6 CEM-T cells were infected with HIV-1 strain IIIB at a moi of 0.005. After overnight incubation, the cells were washed three times with Hanks' balanced salts solution (HBSS) and cultured in medium with R10 (RPMI 1640+10% FBS) for CEM-T cells. At designated days, cell culture supernatant was collected for HIV-1 p24 antigen analysis.
- lentiviral vector-transduced CD34+ cells were propagated in IMDM containing 20% FBS, IL-3 (10 ng/ml), IL-6 (10 ng/ml), and SCF (10 ng/ml) on irradiated human stroma cells for one week.
- CD34+ cells 2 ⁇ 10 5 CD34+ cells were exposed to JR-FL strain of HIV-1 at a moi of 0.01 overnight. The infected cells were washed four times with HBSS and the cultures were continued in the medium containing the cytokines. At designated days, cell culture supernatant was collected for HIV-1 p24 antigen analysis.
- Cells were co-transfected with HIV-1 proviral DNA pNL4-3 and the appropriate shRNA constructs. Culture supernatants were collected at twenty-four hour intervals and analyzed for HIV-1 p24 antigen using an ELISA assay (Beckman Coulter Corp). The p24 values were calculated using a Dynatech MR5000 ELISA plate reader (Dynatech Lab Inc). Cell viability was also performed using a Trypan blue dye exclusion count 4 days post transfection.
- an shRNA consisting of a 28 base pair stem with a 9 base loop specifically targeted to HIV-1 rev was inserted downstream of the ponasterone A inducible promoter (pIND) in two different Pol II expression cassettes, with or without the 5′ leader element of the minimal hsp70 promoter from the pIND vector ( FIG. 1A ).
- pIND ponasterone A inducible promoter
- a minimal polyA sequence was included as previously described (Xia et al., 2002). According to one publication, the 5′ hsp leader element is essential for the transcriptional elongation block observed with the Drosophila hsp70 promoter (Lee et al., 1992).
- the HIV-1 Rev gene was fused to EGFP and expressed in the pIND vector system.
- EGFP fluorescence was observed as early as 3 hours post addition of the inducer ponasterone A and continued for more than 100 hours.
- EcR-293 cells were co-transfected with the various shRNA expression constructs and pIND-REV-EGFP.
- EcR-293 cells are modified HEK 293 cells that stably express the ecdysone receptor and are inducible by the ecdysone analog ponasterone A. Sixteen to twenty hours post transfection, ponasterone A was added to induce the expression of both the shRNA constructs as well as the target rev-EGFP RNA.
- RNAs were isolated from cells either treated or untreated with the inducer ponasterone A and Northern gel analyses were carried out.
- the construct in which the leader element was retained showed inducible expression of a long, unprocessed RNA precursor, but no siRNA sized products.
- RNA based antivirals A number of studies with RNA based antivirals have shown that ribozymes and antisense RNA when expressed from the HIV LTR can efficiently inhibit viral replication in cells infected with HIV (Dropulic et al., 1996; Paik et al., 1997). The expression depends on the presence of the viral transactivator protein TAT which binds to the TAR loop and recruits P-TEFb (P-transcription elongation factor b), a heterodimer of CDK9 and cyclinT1, which in turn phosphorylates the CTD of RNA polymerase and makes it elongation competent (Karn, 1999; Kabor and Greenblatt, 2002). However, it has been previously demonstrated (Xia et al., 2002) and confirmed that shRNAs with appended, non-target derived 5′ extensions do not function effectively in RNAi.
- TAT viral transactivator protein
- P-TEFb P-transcription elongation factor b
- HIV-1 LTR and hsp70 promoter show similar kinetics when activated with heat shock (Kretz-Remy and Arrigo, 1994). It was therefore reasoned that the hsp70 promoter might be regulated by TAT binding to an upstream TAR element.
- the hsp70 core promoter and the shRNAmpolyA cassette from the mpIND-shRNAmpolyA were inserted downstream of the HIV-1 LTR up to and including the TAR sequences ( FIG. 2A ). It was anticipated that transcription from the HIV-1 LTR might stall following transcription of the TAR loop (Palangat et al, 1998) and immediately upstream of the initiation complex assembled at the downstream hsp70 promoter.
- N-TEF negative transcription elongation factors
- NELF negative elongation factor
- DSIF DRB sensitivity inducing factor
- HIV-1 TAT bound to the TAR element upstream of the hsp70 core promoter would recruit P-TEFb, which not only phosphorylates the RD subunit of NELF (Fujinaga et al., 2004) and causes the release of N-TEF, but also in turn could phosphorylate the C terminal domain (CTD) of the RNA polymerase complexed with the hsp70 initiation complex. Phosphorylation of RNAP should relieve this elongation block. The resulting transcript should initiate at position +1 of the shRNA.
- pNL4-3 proviral DNA was transiently co-transfected with the various shRNA constructs into HEK 293 cells. HIV replication was assessed by ELISAs for HIV-encoded p24 in culture supernatants. As can be seen from FIG. 2C , there was an approximate 90% inhibition of HIV-1 gene expression mediated by the LTRhsp-shRNA construct relative to cells transfected with pNL4-3 and irrelevant siRNA, which is comparable to the inhibition observed with the shRNA expressed from mpIND-shRNAmpolyA construct. The hsp70 TATA mutant failed to show any inhibition.
- the HIV-1 TATA box is constitutively bound by the TATA binding protein (TBP) and TBP-associated factors (TAFs) (Mason and Lis, 1997).
- TBP TATA binding protein
- TAFs TBP-associated factors
- This binding might serve as a ‘roadblock’ to transcription originating from the HIV-1 LTR and would cause arrest or at least a decrease in productive transcription from the HIV-1 LTR.
- 293 cells were co-transfected with pNL4-3 and the LTRhsp-shRNA or hsp70 TATA mutant construct.
- this data does not support a ‘roadblock’ model as suggested for some genes regulated by dual promoters or TATA boxes. In those situations, the majority of the transcripts originate from the downstream promoter such as has been reported for the human fatty acid synthase gene (Hsu et al., 1996).
- This data supports a model wherein the hsp70 initiation complex is phosphorylated as a ‘bystander’ due to the P-TEFb, which is recruited in close proximity by the TAT-TAR interaction. It has been shown that a strong transcription pause delays human RNAPII at the base of the TAR loop (position +62) (Palangat et al., 1998).
- This pause is independent of the promoter proximal pausing and would occur even in presence of TAT.
- the pause with a half-life of about 22 seconds, is due to the formation of a hairpin structure which causes the RNAP to reverse translocate by 2 nucleotides. This allows time for the assembly of the initiation complex at the downstream hsp70 promoter.
- This pausing is important to the system as attempts to abolish the pausing by activating transcription from the HIV-1 LTR via the NF- ⁇ B pathway reduced transcription from the hsp70 promoter by a factor of 2 (data not shown).
- the short hairpin RNA expressed from the various promoters consists of two 28 base arms separated by a 9 base loop sequence.
- an shRNA that is processed fully from the 3′ end should result in a transcript that is ⁇ 65 bases in length.
- the partially processed hairpin seen in FIG. 5A was determined to be ⁇ 39-40 bases. This product was not detectable when a probe complementary to the sense strand was used, suggesting a partial processing of some shRNA molecules in which a cleavage eliminates the sense strand, leaving behind the antisense plus all or most of the loop ( FIG. 5B ). This intermediate appears to accumulate to relatively high levels relative to the fully processed siRNAs. At this time it is not known if the partially processed shRNA is a dead end product or an siRNA precursor.
- the LTRhsp-shRNA construct was cloned in pHIV-7 in the reverse orientation.
- pHIV-7 When 293 cells were co-transfected with pNL4-3 and LTRhsp-shRNA in pHIV-7, HIV inducible siRNA expression was observed from this construct in a transient transfection assay (data not shown).
- Primary CD34+ hematopoietic stem cells and CEM T cells were transduced with the LTRhsp-shRNA construct cloned in pHIV-7. The transduced cells were infected with HIV-1 JRFL or HIV-1 IIIB, respectively, at an MOI of 0.005.
- the fusion promoter of the present invention is believed to be the first report of an HIV-1 inducible siRNA system. Earlier studies have shown that TAT can transactivate heterologous promoters when the TAR element is placed downstream of the promoter (Han et al., 1991). A TAT-GAL4 fusion protein has also been shown to activate transcription from downstream promoter elements when targeted to upstream Ga14 binding sites (Southgate and Green, 1991). The present invention thus is believed to provide the first demonstration of a TAR element upstream of a basal promoter element for activation of transcription from the basal promoter.
- the present invention offers a system for inducible expression of a variety of shRNAs, including those to cellular and viral targets.
- a cis-regulatory element of viral or cellular origin can be cloned between the TAR element and the hsp70 promoter or downstream of the minimal polyA, as shown in FIG. 6 .
- the HIV-1 LTR would still be used to transcribe the TAR loop, whose function would be not as a transcriptional activator by recruiting TAT, but as a repressor by recruiting N-TEF.
- N-TEF would suppress the transcription from the hsp70 promoter, as was seen in studies of the system of the invention.
- binding of viral specific or tissue specific transcription factors to the cis-regulatory elements inserted in either of the two places above, as shown in FIG. 6 could phosphorylate the C terminal domain (CTD) of the RNA polymerase complexed with the hsp70 initiation complex. Phosphorylation of RNAP should relieve this elongation block. Using this approach one can use this promoter for inducible expression of siRNA in response to, for example, tissue specific, viral, cellular or engineered transcription factors.
- CTD C terminal domain
- an ecdysone inducible system could be achieved by cloning ecdysone response elements in either of the above places (i.e., between the TAR element and the hsp70 promoter or downstream of the minimal polyA, as shown in FIG. 6 ).
- a drug inducible system although useful in a research setting, may not be practical in a therapeutic setting, as every cell harboring the siRNA construct would express siRNA on administering the drug.
- the system of the present invention could be used to activate anti-HIV-1 sh/siRNAs only in cells infected by an active virus thereby eluding potential toxicities that may ensue with long term expression of sh/siRNAs in a therapeutic setting.
- the fusion promoter system of the invention provides the safety of an HIV-1 inducible system without compromising the efficacy of the antiviral shRNA.
- the TAT inducible system can be utilized for regulated siRNA production against cellular targets by making the TAT expression system itself inducible.
Abstract
An inducible system and methods for controlling expression of siRNA are provided. An inducible system for producing siRNA only in the presence of HIV TAT, and methods for inhibiting HIV-1 gene expression in cells comprising such inducible system also are provided.
Description
- The present application is a continuation of U.S. patent application Ser. No. 11/283,410 filed 21 Nov. 2005, which in turn is related to and claims priority under 35 U.S.C. §119(e) to U.S. provisional patent application Ser. No. 60/629,890 filed 23 Nov. 2004, each of which are incorporated herein by reference.
- The present invention was made in part with Government support under Grant Numbers AI29329, AI42552 and HL074704 awarded by the National Institutes of Health. The Government may have certain rights in this invention.
- The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is entitled 1954561SequenceListing.txt, created on 20 Mar. 2012 and is 1 kb in size. The information in the electronic format of the Sequence Listing is incorporated herein by reference in its entirety.
- The present invention relates to RNA interference. In particular, the invention relates to an inducible system and methods for controlling the expression of siRNA and to use of the system for inhibiting gene expression.
- The publications and other materials used herein to illuminate the background of the invention, and in particular, cases to provide additional details respecting the practice, are incorporated by reference, and for convenience are referenced in the following text by author and date and are listed alphabetically by author in the appended bibliography.
- The proteins mediating RNA interference (RNAi) are part of an evolutionarily conserved cellular pathway that processes endogenous cellular RNAs to silence developmentally important genes (Grishok et al., 2001; Hutvagner et al., 2001). RNAi is a potent inhibitor of targeted gene expression in a wide variety of organisms (Wianny and Zernica-Goetz, 2000; Kennerdell and Carthew, 1998; Fire et al., 1998). The triggers for RNAi are small interfering RNAs (siRNAs) that are processed from long double stranded or hairpin RNA precursors and become part of a ribonucleoprotein complex (Lipardi et al., 2001; Sijen et al., 2001). RNAi mediated gene silencing in mammalian cells has been achieved by either transfecting synthetic dsRNA (Caplan et al., 2001; Elbashir et al., 2001), plasmids (Brummelkamp et al., 2002; Lee et al., 2002; Miyagishi and Taira, 2002) expressing siRNA as individual sense and antisense strands, or the use of short hairpin RNAs (shRNAs) 21-29 nucleotides long which are processed by the RNAse III family member Dicer to siRNA sized molecules that guide the cleavage of cognate mRNA (Xia et al., 2002; An et al., 2003). Most expression systems produce shRNAs from Pol III promoters which provide discrete 5′ and 3′ termini that are further processed into siRNAs. These transcripts mimic micro RNA precursors in structure and are most probably cytoplasmically exported by the transport factor exporting 5 (Ye et al., 2003).
- Early on it was demonstrated that a Pol II promoter could also be used to express shRNAs (Xia et al., 2002). Some of the restrictions for expression of a functional shRNA include elimination of non-base paired 5′ sequences and the use of a minimal poly A signal (Xia et al., 2002). There are several potential advantages to utilizing Pol II expressed shRNAs including tissue specific promoters and inducible transcription. Given the requirement for a poly A signal at the 3′ end of the transcriptional units, it is not known how the final shRNAs are produced, and which transport system is used to export these to the cytoplasm. Nevertheless, it is clear that functional siRNAs can be produced by Pol II systems.
- Small interfering RNAs (siRNAs) can induce potent gene silencing by directing degradation of cognate mRNAs. Controlled expression of siRNA may be important in clinical settings because it has been reported that some siRNA and shRNA sequences can induce a non-specific interferon response. The present invention thus provides controlled expression of siRNA.
- The present invention relates to an inducible system for controlling expression of siRNA, including short hairpin RNA (shRNA). The inducible system comprises a suitable promoter operatively associated with an inducible element. siRNA is preferably produced only in the presence of an inducer which is specific for the inducible element. The invention is useful for inhibiting gene expression.
- In one aspect, the present invention provides an inducible fusion promoter for expressing siRNA or shRNA. The inducible fusion promoter comprises a suitable promoter operatively associated with an inducible element. In one embodiment, the inducible element is responsive to a tissue specific, viral specific, cellular specific or engineered transcription factor. In another embodiment, the inducible element is responsive to a viral specific transcription factor. In a further embodiment, the virus is HIV. In one embodiment, the inducer is TAT. In another embodiment the inducible element is the HIV-1 LTR containing the TAR sequences.
- In a second aspect, the present invention provides for the inducible expression of siRNA (shRNA) in response to an inducer through the use of the inducible fusion promoter to which the siRNA (shRNA) is operably linked. The fusion promoter should express siRNA (shRNA) only in cells that express the inducer. In one embodiment, the cells naturally express the inducer. In another embodiment, the cells are viral infected cells that express the inducer. In a further embodiment, the cells are cells transfected with a vector that expresses the inducer. In one embodiment, the cells are cells harboring HIV-1. In a second embodiment, the cells are cells transfected with a vector expressing the TAT gene.
- In a third aspect, the present invention provides pharmaceutical compositions containing the inducible siRNA (shRNA).
- In a fourth aspect, the present invention provides methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. In one embodiment, the method involves introducing into the environment of a cell an amount of a inducible siRNA (shRNA) such that a sufficient portion of the siRNA (shRNA) can be induced in the cell to cause a reduction in the expression of the target gene.
- siRNA expression according to the present invention translates to an efficient inhibition of gene expression in a transient as well as in a stable long-term setting. These results demonstrate for the first time a functional inducible system for siRNAs which are useful, for example, for siRNA based gene therapy. The present invention is particularly advantageous in that it addresses the safety concerns of off-target effects sometimes or often associated with expression of shRNA. These advantages thus enhance the utility of the present invention in the clinical setting.
-
FIG. 1A shows an shRNA sequence and expression cassettes. In particular, an shRNA sequence (SEQ ID NO:1) with minimal polyadenylation signal sequence is shown. One of the boxes shows the position of the G-U wobble pairing. Also shown is a schematic representation of the pIND expression cassette from the pIND vector (Invitrogen) and shRNA expression cassette with and without the 5′ leader element of the minimal hsp70 promoter from the pIND vector. B=Bgl II site; X=Xma I site; TS=Transcription start; MCS=Multiple cloning site; LE=Leader element; S=Sense strand; AS=Antisense strand; L=Loop. -
FIG. 1B are photographs showing inhibition of RevEGFP expression by shRNAs. EcR-293 cells were co-transfected with pIND-RevEGFP and shRNA constructs in the presence and absence of ponasterone, as indicated. Cells were examined microscopically for EGFP expression as described in the Examples. The right panels in all cases are phase contrast images taken at the time of fluorescent microscope analysis (left panels) showing that approximately equivalent numbers of cells are present in each field. Cells transfected with shRNA construct without the leader element removed showed an approximate 90% reduction in fluorescent cells. Cells transfected with pIND-shRNA showed EGFP expression levels similar to that observed with cells transfected with only the Rev-EGFP construct. Specific silencing of Rev-EGFP was confirmed by at least three independent experiments. -
FIG. 1C shows results of a Northern blot analysis of EcR-293 cells transfected with shRNA constructs in the presence and absence of ponasterone, as indicated. mpIND-shRNAmpolyA construct showed expression and processing to siRNA-sized products, both in the presence and absence of the inducer while the construct with the leader element showed no processing even in the presence of the inducer. Upper arrow indicates primary transcript region, the lower bands indicate partially processed hairpin and siRNAs, respectively. The strong band in all lanes is an unknown cellular transcript that has homology to the oligonucleotide probe. M=Marker (21 nucleotide RNA). -
FIG. 1D is a graph showing inhibition of HIV-1 gene expression by shRNA constructs. EcR-293 cells were co-transfected with wild type infectious proviral DNA, pNL4-3 and mpIND-shRNAmpolyA in the presence and absence of ponasterone, as indicated. Inhibition is seen both in the presence and absence of the inducer. -
FIG. 1E shows results of a Northern blot analysis of total RNA extracted from the above cells and shows that siRNA expression and processing occurs both in the presence and absence of the inducer. The arrows indicate partially processed and fully processed shRNAs and siRNAs, respectively. The strong band in all lanes is a cellular transcript that has homology to the oligonucleotide probe. -
FIG. 2A shows a schematic representation of LTRhsp-shRNA. HIV-1 LTR along with the TAR loop region was cloned upstream of the minimal hsp70 promoter. -
FIG. 2B shows results of a Northern blot analysis of 293 cells and shows Tat inducible expression of shRNAs. Cells were co-transfected with LTRhsp-shRNA or the hsp70 TATA mutated construct in the presence or absence of a Tat expressing plasmid, as indicated. Expression and processing to siRNA-sized products was only observed in the presence of Tat. The hsp70 TATA mutated construct did not show any processing. mpIND-shRNAmpolyA was transfected as a Pol II expressed shRNA control. Arrows indicate partially processed precursor and siRNA sized products. The strong band common to all lanes is an endogenous sequence with homology to the antisense olignucleotide probe. C=Cell control; M=Marker (21 nucleotide RNA). -
FIG. 2C is a graph showing Inhibition of HIV gene expression by LTRhsp-shRNA. 293 cells were co-transfected with pNL4-3 and fold decrease in HIV-1 p24 is observed in cells transfected with LTRhsp-shRNA. The level of inhibition was comparable to that observed with mpIND-shRNAmpolyA which was used as Pol II expressed shRNA control. -
FIG. 2D shows results of a Northern blot analysis of total RNA extracted from the above cells and shows efficient expression and processing in cells transfected with LTRhsp-shRNA and mpIND-shRNAmpolyA. The siRNA sized products are indicated, the band above these is the partially processed shRNA. C=Cell control; M=Marker (21 nucleotide RNA). -
FIG. 3A shows a schematic representation of a packaging system useful for inhibition of HIV-1 replication. The lentiviral vector, pHIV-7-GFP, contains a hybrid 5′ LTR in which the U3 region is replaced with the CMV promoter, the packaging signal (Ψ), the RRE sequence, the EGFP gene driven by CMV promoter, and the 3′ LTR in which the cis regulatory sequences are completely removed from the U3 region. LTRhsp-shRNA mpolyA is inserted directly upstream of the CMV promoter of EGFP in pHIV-7-GFP vector in the reverse orientation. The solid box between RRE and CMV-EGFP represents the FLAP sequence of HIV-1. pCHGP-2 contains the gag and pol genes and RRE sequence from HIV-1 under the control of the CMV promoter. pCMV-Rev contains the coding sequence of Rev driven by the CMV promoter. pCMV-G contains the VSV-G protein gene under the control of the CMV promoter. pA indicates the polyadenylation signal from the human β-globin gene. -
FIGS. 3B and 3C show the results of an HIV-1 challenge assay. CD34 stem cells or CEM cells transduced with pHIV-7-LTRhspshRNA were challenged with a JRFL or HIV-1 IIIB strain, respectively. Culture supernatants were collected and p24 ELISA was carried out as described in the Examples. LTRshREV=LTRhsp-shRNA cloned in the reverse orientation. -
FIG. 4 is a gel photograph showing transcription occurring from both HIV-1 LTR and mhsp70 TATA boxes. 293 cells were co-transfected with pNL4-3 and LTRhsp-shRNA or hsp70 TATA mutant. 50 ngs of Total RNA was used for RT-PCR analysis using primers flanking the HIV-1 TAR and hsp70 TATA box sequences. Lanes corresponding to the LTRhsp-shRNA and the hsp70 TATA mutant showed signals of similar intensity. GAPDH was amplified as an internal control. -
FIGS. 5A and 5B show partial processing of an shRNA loop. InFIG. 5A , the results of a Northern blot analysis are shown in which total RNA is extracted from 293 cells co-transfected with shRNA constructs and pNL4-3. A strong 39 base partially processed form can be observed when the blot was probed to detect the antisense strand. This product was observed when the blot was probed to detect the antisense strand. This product was not detectable when a probe complementary to the sense strand was used. The upper band is the partially processed shRNA and the lower band is the fully processed siRNA.FIG. 5B is a schematic depiction of shRNA processing. An shRNA that is processed fully from the 3′ end should result in three molecular species, a partially processed hairpin with the loop processed at the 5′ end of the antisense strand, a fully processed loop and a partially processed species with the loop processed at the 3′ end of the sense strand ofsize ca 39 bases. -
FIG. 6 is a schematic representation of a general inducible system using a fusion promoter according to the invention. The cis-acting regulatory elements are cloned either between the TAR loop and the minimal hsp70 promoter, as shown, or downstream of the minimal polyadenylation signal sequence (mpolyA). Transcription of the TAR loop by the HIV-1 LTR recruits N-TEF components NELF (tetramer) and DSIF (dimer). These in turn suppress transcription from the hsp70 promoter as well as HIV-1 LTR. Binding of cis-acting transcriptional activators either downstream of the minimal polyA or between the TAR loop and the minimal hsp70 promoter activates shRNA transcription from the hsp70 promoter. - The present invention relates to an inducible system for controlling expression of siRNA, including short hairpin RNA (shRNA). The inducible system comprises a nucleic acid construct that comprises a suitable promoter operatively associated with an inducible element. The nucleic acid construct may also further comprise siRNA (shRNA) operably associated with the promoter. The siRNA is preferably produced only in the presence of an inducer which is specific for the inducible element. The invention is useful for inhibiting gene expression.
- As used herein, “nucleic acid construct” or “construct” refers to an isolated polynucleotide which is introduced into a host cell. This construct may comprise any combination of deoxyribonucleotides, ribonucleotides, and/or modified nucleotides. The construct may be transcribed to form an RNA, wherein the RNA may be capable of forming a double-stranded RNA and/or hairpin structure. This construct may be expressed in the cell, or isolated or synthetically produced. The construct may further comprise a promoter, or other sequences which facilitate manipulation or expression of the construct.
- In one aspect, the present invention provides an inducible fusion promoter for expressing siRNA or shRNA. The inducible fusion promoter is a nucleic acid construct that comprises a suitable promoter operatively associated with an inducible element. In one embodiment, the inducible element is responsive to an inducer. In another embodiment, the inducer is a tissue specific transcription factor, a viral specific transcription factor, a cellular specific transcription factor or an engineered transcription factor. In further embodiment, the inducible element is responsive to a viral specific transcription factor. In a still further embodiment, the virus is HIV. In one embodiment, the inducer is TAT. In another embodiment the inducible element is the HIV-1 LTR containing the TAR sequences.
- As used herein “operably linked” or “operably associated” includes reference to a functional linkage of at least two sequences. For example, operably linked includes linkage between a promoter and a second sequence, wherein the promoter sequence initiates and mediates transcription of the DNA sequence corresponding to the second sequence. Operably associated includes linkage between an inducing element and a promoter, wherein the inducing element acts as a transcriptional activator of the promoter.
- As used herein, “promoter” includes reference to a region of DNA that is involved in recognition and binding of an RNA polymerase and other proteins to initiate transcription. In one embodiment, the promoter is a Pol II promoter. Any Pol II promoter may be used in accordance with the present invention. In one embodiment, the Pol II promoter is a heat shock promoter. In another embodiment, the heat shock promoter is a minimal heat shock promoter. In a further embodiment, the minimal heat shock promoter is the Drosophila hsp70 minimal heat shock promoter.
- As used herein, an “inducible element” includes an element that confers regulation on transcription of a downstream expressed region under inducing conditions. It may be obtained from enhancer regions that are also inducible. Removal of an inducible element from the downstream expressed region would be expected to decrease expression of a downstream region under inducing conditions. Inducible elements (e.g., consensus sequences known in the art) are usually between about 4 and 100 nucleotides in length.
- In one embodiment, the inducible element is HIV-1 TAR (transactivation-responsive region). TAR resides within the R region of the HIV-1 long terminal repeat (LTR), between −17 and +54 with respect to the initiation site of viral transcription (Feng and Holland, 1988; Rosen et al., 1985; Muesing et al., 1987). The RNA encoded between +1 and +59 has the potential to from an extensive stem-loop secondary structure which, as a portion of the untranslated leader RNA, would be common to all HIV-1 mRNAs (Muesing et al., 1987; Okamoto and Wong-Staal, 1986). Studies have shown that the sequence +30CUGGG+34 in TAR within the loop of the hairpin structure is required for TAT transactivation (Feng and Holland, 1988).
- As used herein, “encodes” or “encoding” refers to a DNA sequence which can be processed to generate an RNA and/or polypeptide.
- As used herein, “inducer” includes an agent that induces, especially a substance that is capable of activating transcription from specific genes within a cell.
- In one embodiment, the inducer is HIV-1 TAT (trans-activator of transcription). HIV-1 TAT is a 14 kDa viral protein involved in the regulation of HIV-1 transcriptional elongation (Kao et al., 1987; Feinberg et al., 1991; Marciniak and Sharp, 1991) and in its presence, viral replication increases by greater than 100-fold (Cullen, 1986; Muesing et al., 1987). It functions to trigger efficient RNA chain elongation by binding to TAR RNA, which forms the initial portion of the HIV-1 transcript (Berkhout et al., 1989). The interaction between TAT and TAR is critical for virus replication and mutations in TAT that alter the RNA-binding site result in defective viruses. Furthermore, virus replication can be strongly inhibited by the overexpression of TAR RNA sequences that act as competitive inhibitors of regulatory protein binding (Graham and Maio, 1990).
- In a preferred embodiment, the present invention relates to an HIV inducible shRNA system, preferably containing a suitable promoter operably associated with an inducible element that is inducible by HIV TAT. In one embodiment, part of a TATA box region, such as the Drosophila hsp70 TATA box region, is cloned downstream of the HIV-1 LTR containing the TAR region.
- In one embodiment of the invention, an anti-HIV shRNA expressed from a Pol II promoter was demonstrated to inhibit HIV-1 gene expression in mammalian cells. This preferred strategy was applied to design a novel promoter system where, in a preferred embodiment, the HIV-1 LTR is fused to the Drosophila hsp70 minimal heat shock promoter. This system is inducible by HIV-1 TAT, providing regulated expression of the shRNA.
- In another aspect of the invention, an inducible system comprises a suitable promoter operatively associated with an HIV TAR region, which instead of acting as a transcriptional activator by recruiting TAT, acts as a repressor by recruiting, for example, N-TEF, thereby suppressing transcription from the promoter. siRNA (shRNA) expression then can be induced in response to inducing elements (e.g., transcription factors) associating with inducible elements (e.g., regulatory elements), which also can be operatively associated with the promoter.
- In still another aspect of the invention, a nucleic acid construct is provided to encode the siRNA (shRNA) for any specific target sequence. Any siRNA (shRNA) can be inserted into the construct containing the inducible system, such that the encoded siRNA (shRNA) selectively targets and suppresses the target sequence.
- A cell containing a nucleic acid construct of the present invention is also provided. By “host cell” is meant a cell which contains an introduced nucleic acid construct and supports the replication and/or expression of the construct. In one embodiment, the cell is a cell that naturally contains the inducer. In another embodiment, the cell is one that is infected by HIV-1, and thus produces TAT. In one embodiment, cells infected with HIV-1 can efficiently induce siRNA (shRNA) expression from a construct according to the present invention. In a further embodiment, the cell is one that is transfected with a nucleic acid construct comprising a TAT coding sequence operably linked to a promoter, such that TAT is produced in the cell. The promoter associated with the TAT encoding nucleic acid sequence may be any promoter, such as a constitutive promoter, a tissue-preferred promoter, an inducible promoter or a derepressible promoter.
- The term “introducing” encompasses a variety of methods of introducing DNA into a cell, either in vitro or in vivo, such methods including transformation, transduction, transfection, and infection. Vectors are useful and preferred agents for introducing DNA encoding the interfering RNA molecules into cells. Possible vectors include plasmid vectors and viral vectors. Viral vectors include retroviral vectors, lentiviral vectors, or other vectors such as adenoviral vectors or adeno-associated vectors.
- In a further aspect of the invention, a method for suppressing a target sequence is provided. The method employs the constructs above, in which a siRNA (shRNA) is designed to a region of the target sequence, and inserted into the construct. Upon introduction into a cell and upon induction of the inducible system, the siRNA (shRNA) produced suppresses expression of the targeted sequence. In one embodiment, the cell is one that is infected with HIV-1, and the invention provides a method of inhibiting viral replication, thus establishing a negative feedback loop. In another embodiment, the cell is one that is transfected with a nucleic acid construct comprising a nucleic acid sequence encoding TAT, and the invention provides a method of inhibiting any target sequence.
- Transformation protocols as well as protocols for introducing nucleotide sequences into cells may vary depending on the type of cell targeted for transformation. Suitable methods of introducing the DNA construct into cells are well known in the art and include microinjection, electroporation, direct gene transfer, ballistic particle transformation, viral transformation, retroviral transformation and the like.
- In some embodiments, transient expression may be desired. In those cases, standard transient transformation techniques may be used. Such methods include, but are not limited to viral transformation methods, and microinjection of DNA or RNA, as well other methods well known in the art.
- Initial identification and selection of cells and/or plants comprising the DNA constructs may be facilitated by the use of marker genes. Gene targeting can be performed without selection if there is a sensitive method for identifying recombinants, for example if the targeted gene modification can be easily detected by PCR analysis, or if it results in a certain phenotype. However, in most cases, identification of gene targeting events will be facilitated by the use of markers. Useful markers include positive and negative selectable markers as well as markers that facilitate screening, such as visual markers.
- Interfering RNA (RNAi) molecules, and more preferably siRNA molecules, produced and/or used in accordance with the invention include those types known in the art. The RNAi, and preferably siRNA, or shRNA, molecules are double-stranded (ds) RNAs, i.e., RNAs that contain a duplex region, that preferably contain about 19 to 23, or 21 to 29, base pairs, respectively. The molecules also preferably contain 3′ overhangs, more preferably 3′UU or 3′TT overhangs. Each strand of the double stranded nucleic acid may comprise RNA, RNA analog(s) or RNA and DNA. Typically, the antisense strand of the siRNA is sufficiently complementary with the target sequence of the target gene. The siRNA and shRNA constructs are designed and prepared using techniques well known in the art, including those described in copending application Ser. No. 11/079,906 filed on 15 Mar. 2005, incorporated herein by reference. The siRNA or shRNA is operably associated with the inducible fusion promoter of the present invention.
- The phrase “duplex region” refers to the region in two complementary or substantially complementary oligonucleotides that form base pairs with one another, either by Watson-Crick base pairing or any other manner that allows for a duplex between oligonucleotide strands that are complementary or substantially complementary. For example, an oligonucleotide strand having 21 nucleotide units can base pair with another oligonucleotide of 21 nucleotide units, yet only 19 bases on each strand are complementary or substantially complementary, such that the “duplex region” consists of 19 base pairs. The remaining base pairs may, for example, exist as 5′ and 3′ overhangs. Further, within the duplex region, 100% complementarity is not required; substantial complementarity is allowable within a duplex region. Substantial complementarity refers to complementarity between the strands such that they are capable of annealing under biological conditions. Techniques to empirically determine if two strands are capable of annealing under biological conditions are well know in the art. Alternatively, two strands can be synthesized and added together under biological conditions to determine if they anneal to one another.
- As is known, RNAi methods are applicable to a wide variety of genes in a wide variety of organisms and the disclosed compositions and methods can be utilized in each of these contexts. Examples of genes which can be targeted by the disclosed compositions and methods include endogenous genes which are genes that are native to the cell or to genes that are not normally native to the cell. Without limitation these genes include oncogenes, cytokine genes, idiotype (Id) protein genes, prion genes, genes that expresses molecules that induce angiogenesis, genes for adhesion molecules, cell surface receptors, proteins involved in metastasis, proteases, apoptosis genes, cell cycle control genes, genes that express EGF and the EGF receptor, multi-drug resistance genes, such as the MDR1 gene.
- As used herein, the phrases “target sequence” and “sequence of interest” are used interchangeably. Target sequence is used to mean the nucleic acid sequence that is selected for suppression of expression, and is not limited to polynucleotides encoding polypeptides. The target sequence comprises a sequence that is substantially or completely complementary to the miRNA. The target sequence can be RNA or DNA, and may also refer to a polynucleotide comprising the target sequence.
- As used herein, “nucleic acid” means a polynucleotide and includes single or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases. Nucleic acids may also include fragments and modified nucleotides.
- As used herein, “vector” includes reference to a nucleic acid used in introduction of a polynucleotide of the invention into a host cell. Expression vectors permit transcription of a nucleic acid inserted therein.
- More specifically, the target mRNA of the invention specifies the amino acid sequence of a cellular protein (e.g., a nuclear, cytoplasmic, transmembrane, or membrane-associated protein). In another embodiment, the target mRNA of the invention specifies the amino acid sequence of an extracellular protein (e.g., an extracellular matrix protein or secreted protein). As used herein, the phrase “specifies the amino acid sequence” of a protein means that the mRNA sequence is translated into the amino acid sequence according to the rules of the genetic code. The following classes of proteins are listed for illustrative purposes: developmental proteins (e.g., adhesion molecules, cyclin kinase inhibitors, Wnt family members, Pax family members, Winged helix family members, Hox family members, cytokines/lymphokines and their receptors, growth/differentiation factors and their receptors, neurotransmitters and their receptors); oncogene-encoded proteins (e.g., ABLI, BCLI, BCL2, BCL6, CBFA2, CBL, CSFIR, ERBA, ERBB, EBRB2, ETSI, ETSI, ETV6, FGR, FOS, FYN, HCR, HRAS, JUN, KRAS, LCK, LYN, MDM2, MLL, MYB, MYC, MYCLI, MYCN, NRAS, PIM I, PML, RET, SRC, TALI, TCL3, and YES); tumor suppressor proteins (e.g., APC, BRCA1, BRCA2, MADH4, MCC, NF I, NF2, RB I, TP53, and WTI); and enzymes (e.g., ACC synthases and oxidases, ACP desaturases and hydroxylases, ADP-glucose pyrophorylases, ATPases, alcohol dehydrogenases, amylases, amyloglucosidases, catalases, cellulases, chalcone synthases, chitinases, cyclooxygenases, decarboxylases, dextriinases, DNA and RNA polymerases, galactosidases, glucanases, glucose oxidases, granule-bound starch synthases, GTPases, helicases, hernicellulases, integrases, inulinases, invertases, isomerases, kinases, lactases, lipases, lipoxygenases, lysozymes, nopaline synthases, octopine synthases, pectinesterases, peroxidases, phosphatases, phospholipases, phosphorylases, phytases, plant growth regulator synthases, polygalacturonases, proteinases and peptidases, pullanases, recombinases, reverse transcriptases, RUBISCOs, topoisomerases, and xylanases).
- In one aspect, the target mRNA molecule of the invention specifies the amino acid sequence of a protein associated with a pathological condition. For example, the protein may be a pathogen-associated protein (e.g., a viral protein involved in immunosuppression of the host, replication of the pathogen, transmission of the pathogen, or maintenance of the infection), or a host protein which facilitates entry of the pathogen into the host, drug metabolism by the pathogen or host, replication or integration of the pathogen's genome, establishment or spread of infection in the host, or assembly of the next generation of pathogen. Pathogens include RNA viruses such as flaviviruses, picornaviruses, rhabdoviruses, filoviruses, retroviruses, including lentiviruses, or DNA viruses such as adenoviruses, poxviruses, herpes viruses, cytomegaloviruses, hepadnaviruses or others. Additional pathogens include bacteria, fungi, helminths, schistosomes and trypanosomes. Other kinds of pathogens can include mammalian transposable elements. Alternatively, the protein may be a tumor-associated protein or an autoimmune disease-associated protein.
- The target gene may be derived from or contained in any organism. The organism may be a plant, animal, protozoa, bacterium, virus or fungus. See e.g., U.S. Pat. No. 6,506,559, incorporated herein by reference.
- In another aspect, the present invention provides for a pharmaceutical composition comprising the dsRNA of the present invention. The dsRNA sample can be suitably formulated and introduced into the environment of the cell by any means that allows for a sufficient portion of the sample to enter the cell to induce gene silencing, if it is to occur. Many formulations for dsRNA are known in the art and can be used so long as dsRNA gains entry to the target cells so that it can act. See, e.g., U.S. published patent application Nos. 2004/0203145 A1 and 2005/0054598 A1, each incorporated herein by reference. For example, dsRNA can be formulated in buffer solutions such as phosphate buffered saline solutions, liposomes, micellar structures, and capsids. Formulations of dsRNA with cationic lipids can be used to facilitate transfection of the dsRNA into cells. For example, cationic lipids, such as lipofectin (U.S. Pat. No. 5,705,188, incorporated herein by reference), cationic glycerol derivatives, and polycationic molecules, such as polylysine (published PCT International Application WO 97/30731, incorporated herein by reference), can be used. Suitable lipids include Oligofectamine, Lipofectamine (Life Technologies), NC388 (Ribozyme Pharmaceuticals, Inc., Boulder, Colo.), or FuGene 6 (Roche) all of which can be used according to the manufacturer's instructions.
- It can be appreciated that the method of introducing dsRNA into the environment of the cell will depend on the type of cell and the make up of its environment. For example, when the cells are found within a liquid, one preferable formulation is with a lipid formulation such as in lipofectamine and the dsRNA can be added directly to the liquid environment of the cells. Lipid formulations can also be administered to animals such as by intravenous, intramuscular, or intraperitoneal injection, or orally or by inhalation or other methods as are known in the art. When the formulation is suitable for administration into animals such as mammals and more specifically humans, the formulation is also pharmaceutically acceptable. Pharmaceutically acceptable formulations for administering oligonucleotides are known and can be used. In some instances, it may be preferable to formulate dsRNA in a buffer or saline solution and directly inject the formulated dsRNA into cells, as in studies with oocytes. The direct injection of dsRNA duplexes may also be done. For suitable methods of introducing dsRNA see U.S. published patent application No. 2004/0203145 A1, incorporated herein by reference.
- Suitable amounts of dsRNA must be introduced and these amounts can be empirically determined using standard methods. Typically, effective concentrations of individual dsRNA species in the environment of a cell will be about 50 nanomolar or less 10 nanomolar or less, or compositions in which concentrations of about 1 nanomolar or less can be used. In other embodiment, methods utilize a concentration of about 200 picomolar or less and even a concentration of about 50 picomolar or less can be used in many circumstances.
- The method can be carried out by addition of the dsRNA compositions to any extracellular matrix in which cells can live provided that the dsRNA composition is formulated so that a sufficient amount of the dsRNA can enter the cell to exert its effect. For example, the method is amenable for use with cells present in a liquid such as a liquid culture or cell growth media, in tissue explants, or in whole organisms, including animals, such as mammals and especially humans.
- The dsRNA can be formulated as a pharmaceutical composition which comprises a pharmacologically effective amount of a dsRNA and pharmaceutically acceptable carrier. A pharmacologically or therapeutically effective amount refers to that amount of a dsRNA effective to produce the intended pharmacological, therapeutic or preventive result. The phrases “pharmacologically effective amount” and “therapeutically effective amount” or simply “effective amount” refer to that amount of an RNA effective to produce the intended pharmacological, therapeutic or preventive result. For example, if a given clinical treatment is considered effective when there is at least a 20% reduction in a measurable parameter associated with a disease or disorder, a therapeutically effective amount of a drug for the treatment of that disease or disorder is the amount necessary to effect at least a 20% reduction in that parameter.
- The phrase “pharmaceutically acceptable carrier” refers to a carrier for the administration of a therapeutic agent. Exemplary carriers include saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. For drugs administered orally, pharmaceutically acceptable carriers include, but are not limited to pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservatives. Suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, while corn starch and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin, while the lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract. The pharmaceutically acceptable carrier of the disclosed dsRNA composition may be micellar structures, such as a liposomes, capsids, capsoids, polymeric nanocapsules, or polymeric microcapsules.
- Polymeric nanocapsules or microcapsules facilitate transport and release of the encapsulated or bound dsRNA into the cell. They include polymeric and monomeric materials, especially including polybutylcyanoacrylate. A summary of materials and fabrication methods has been published (see Kreuter, 1991). The polymeric materials which are formed from monomeric and/or oligomeric precursors in the polymerization/nanoparticle generation step, are per se known from the prior art, as are the molecular weights and molecular weight distribution of the polymeric material which a person skilled in the field of manufacturing nanoparticles may suitably select in accordance with the usual skill.
- Suitably formulated pharmaceutical compositions of this invention can be administered by any means known in the art such as by parenteral routes, including intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, airway (aerosol), rectal, vaginal and topical (including buccal and sublingual) administration. In some embodiments, the pharmaceutical compositions are administered by intravenous or intraparenteral infusion or injection.
- In general a suitable dosage unit of dsRNA will be in the range of 0.001 to 0.25 milligrams per kilogram body weight of the recipient per day, or in the range of 0.01 to 20 micrograms per kilogram body weight per day, or in the range of 0.01 to 10 micrograms per kilogram body weight per day, or in the range of 0.10 to 5 micrograms per kilogram body weight per day, or in the range of 0.1 to 2.5 micrograms per kilogram body weight per day. Pharmaceutical composition comprising the dsRNA can be administered once daily. However, the therapeutic agent may also be dosed in dosage units containing two, three, four, five, six or more sub-doses administered at appropriate intervals throughout the day. In that case, the dsRNA contained in each sub-dose must be correspondingly smaller in order to achieve the total daily dosage unit. The dosage unit can also be compounded for a single dose over several days, e.g., using a conventional sustained release formulation which provides sustained and consistent release of the dsRNA over a several day period. Sustained release formulations are well known in the art. In this embodiment, the dosage unit contains a corresponding multiple of the daily dose. Regardless of the formulation, the pharmaceutical composition must contain dsRNA in a quantity sufficient to inhibit expression of the target gene in the animal or human being treated. The composition can be compounded in such a way that the sum of the multiple units of dsRNA together contain a sufficient dose.
- Data can be obtained from cell culture assays and animal studies to formulate a suitable dosage range for humans. The dosage of compositions of the invention lies within a range of circulating concentrations that include the ED50 (as determined by known methods) with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range of the compound that includes the IC50 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels of dsRNA in plasma may be measured by standard methods, for example, by high performance liquid chromatography.
- In a further aspect, the present invention relates to a method for treating a subject having a disease or at risk of developing a disease caused by the expression of a target gene. In this embodiment, the dsRNA can act as novel therapeutic agents for controlling one or more of cellular proliferative and/or differentiative disorders, disorders associated with bone metabolism, immune disorders, hematopoietic disorders, cardiovascular disorders, liver disorders, viral diseases, or metabolic disorders. The method comprises administering a pharmaceutical composition of the invention to the patient (e.g., human), such that expression of the target gene is silenced. Because of their high specificity, the dsRNAs of the present invention specifically target mRNAs of target genes of diseased cells and tissues.
- In the prevention of disease, the target gene may be one which is required for initiation or maintenance of the disease, or which has been identified as being associated with a higher risk of contracting the disease. In the treatment of disease, the dsRNA can be brought into contact with the cells or tissue exhibiting the disease. For example, dsRNA substantially identical to all or part of a mutated gene associated with cancer, or one expressed at high levels in tumor cells, e.g. aurora kinase, may be brought into contact with or introduced into a cancerous cell or tumor gene.
- Examples of cellular proliferative and/or differentiative disorders include cancer, e.g., carcinoma, sarcoma, metastatic disorders or hematopoietic neoplastic disorders, e.g., leukemias. A metastatic tumor can arise from a multitude of primary tumor types, including but not limited to those of prostate, colon, lung, breast and liver origin. As used herein, the terms “cancer,” “hyperproliferative,” and “neoplastic” refer to cells having the capacity for autonomous growth, i.e., an abnormal state of condition characterized by rapidly proliferating cell growth. These terms are meant to include all types of cancerous growths or oncogenic processes, metastatic tissues or malignantly transformed cells, tissues, or organs, irrespective of histopathologic type or stage of invasiveness. Proliferative disorders also include hematopoietic neoplastic disorders, including diseases involving hyperplastic/neoplatic cells of hematopoictic origin, e.g., arising from myeloid, lymphoid or erythroid lineages, or precursor cells thereof.
- The present invention can also be used to treat a variety of immune disorders, in particular those associated with overexpression of a gene or expression of a mutant gene. Examples of hematopoietic disorders or diseases include, without limitation, autoimmune diseases (including, for example, diabetes mellitus, arthritis (including rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis), multiple sclerosis, encephalomyelitis, myasthenia gravis, systemic lupus erythematosis, automimmune thyroiditis, dermatitis (including atopic dermatitis and eczematous dermatitis), psoriasis, Sjogren's Syndrome, Crohn's disease, aphthous ulcer, iritis, conjunctivitis, keratoconjunctivitis, ulcerative colitis, asthma, allergic asthma, cutaneous lupus erythematosus, scleroderma, vaginitis, proctitis, drug eruptions, leprosy reversal reactions, erythema nodosum leprosum, autoimmune uveitis, allergic encephalomyclitis, acute necrotizing hemorrhagic encephalopathy, idiopathic bilateral progressive sensorineural hearing, loss, aplastic anemia, pure red cell anemia, idiopathic thrombocytopenia, polychondritis, Wegener's granulomatosis, chronic active hepatitis, Stevens-Johnson syndrome, idiopathic sprue, lichen planus, Graves' disease, sarcoidosis, primary biliary cirrhosis, uveitis posterior, and interstitial lung fibrosis), graft-versus-host disease, cases of transplantation, and allergy.
- In another embodiment, the invention relates to a method for treating viral diseases, including but not limited to human papilloma virus, hepatitis C, hepatitis B, herpes simplex virus (HSV), HIV-AIDS, poliovirus, and smallpox virus. dsRNAs of the invention are prepared as described herein to target expressed sequences of a virus, thus ameliorating viral activity and replication. The molecules can be used in the treatment and/or diagnosis of viral infected tissue, both animal and plant. Also, such molecules can be used in the treatment of virus-associated carcinoma, such as hepatocellular cancer.
- The dsRNA of the present invention can also be used to inhibit the expression of the
multi-drug resistance 1 gene (“MDR1”). “Multi-drug resistance” (MDR) broadly refers to a pattern of resistance to a variety of chemotherapeutic drugs with unrelated chemical structures and different mechanisms of action. Although the etiology of MDR is multifactorial, the overexpression of P-glycoprotein (Pgp), a membrane protein that mediates the transport of MDR drugs, remains the most common alteration underlying MDR in laboratory models (Childs and Ling, 1994). Moreover, expression of Pgp has been linked to the development of MDR in human cancer, particularly in the leukemias, lymphomas, multiple myeloma, neuroblastoma, and soft tissue sarcoma (Fan et al.). Recent studies showed that tumor cells expressing MDR-associated protein (MRP) (Cole et al., 1992), lung resistance protein (LRP) (Scheffer et al., 1995) and mutation of DNA topoisomerase II (Beck, 1989) also may render MDR. - The practice of the present invention employs, unless otherwise indicated, conventional techniques of chemistry, molecular biology, microbiology, recombinant DNA, genetics, immunology, cell biology, cell culture and transgenic biology, which are within the skill of the art. See, e.g., Maniatis et al., 1982, Molecular Cloning (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.); Sambrook et al., 1989, Molecular Cloning, 2nd Ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.); Sambrook and Russell, 2001, Molecular Cloning, 3rd Ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.); Ausubel et al., 1992), Current Protocols in Molecular Biology (John Wiley & Sons, including periodic updates); Glover, 1985, DNA Cloning (IRL Press, Oxford); Anand, 1992; Guthrie and Fink, 1991; Harlow and Lane, 1988, Antibodies, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.); Jakoby and Pastan, 1979; Nucleic Acid Hybridization (B. D. Hames & S. J. Higgins eds. 1984); Transcription And Translation (B. D. Hames & S. J. Higgins eds. 1984); Culture Of Animal Cells (R. I. Freshney, Alan R. Liss, Inc., 1987); Immobilized Cells And Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide To Molecular Cloning (1984); the treatise, Methods In Enzymology (Academic Press, Inc., N.Y.); Gene Transfer Vectors For Mammalian Cells (J. H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor Laboratory); Methods In Enzymology, Vols. 154 and 155 (Wu et al. eds.), Immunochemical Methods In Cell And Molecular Biology (Mayer and Walker, eds., Academic Press, London, 1987); Handbook Of Experimental Immunology, Volumes I-IV (D. M. Weir and C. C. Blackwell, eds., 1986); Riott, Essential Immunology, 6th Edition, Blackwell Scientific Publications, Oxford, 1988; Hogan et al., Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986); Westerfield, M., The zebrafish book. A guide for the laboratory use of zebrafish (Danio rerio), (4th Ed., Univ. of Oregon Press, Eugene, 2000).
- The present invention is described by reference to the following Examples, which are offered by way of illustration and are not intended to limit the invention in any manner. Standard techniques well known in the art or the techniques specifically described below were utilized.
- The siRNA was designed to target a highly accessible site in the HIV-1 rev transcript as previously reported (Lee et al., 2002). The shRNA design involved extending the sense strand by eight nucleotides on the 3′ end to obtain a 28-nucleotide stem. A single C to U point mutation was designed in the center of the sense strand to facilitate cloning. The sequence of the 9 base loop was described previously by Xia et al. (2002).
- Construction and characteristics of the plasmid pIND RevEGFP have been previously described (Lee et al., 2002). In order to create the vector pIND-shRNA, two PCR reactions were carried out.
- A) The pIND promoter was amplified by PCR using primers that would amplify the promoter alone, or the promoter plus the 5′ leader sequence from the pIND vector (Invitrogen).
- B) For PCR amplification of shRNAmpolyA, two overlapping oligonucleotides were designed:
-
(SEQ ID NO: 2) 5′-GCCTGTGCCTCTTCAGTTACCGCTTGAGTTCAAGAGACTCAAGCGG TAGCTGAAGAGGCACAGGCTTCTAGAACTAGTAATAAAGGATCC-3′ (SEQ ID NO: 3) 5′-CGGTCTAGACGCGGCCGCACACAAAAAACCAACACACGGATCCAAT GAAAATAAAGGATCCTTTATTACTAGTTCTAGAAGC-3′.
These were annealed and primer extended in the presence of dNTPs and further amplified by PCR. - The PCR products from both of the above reactions were blunt end ligated to one another and cloned in the pCR2.1 vector (Invitrogen). The construct without the leader element was designated as mpIND-shRNAmpolyA and the construct with the leader element was called pIND-shRNAmpolyA.
- For construction of the LTRhsp-shRNA, the E/GRE elements were removed from the mpIND-shRNAmpolyA construct using Bgl II and Xma I and the pNL4-3 derived HIV-1 LTR was inserted in the same position (
FIG. 2A ). The hsp70 TATA mutant construct was obtained by mutating the hsp70 TATA box to a Cla I site. - Construction and characteristics of the lentiviral vector pHIV-7 have been previously described (Gasmi et al., 1999). For pHIV-LTRhsp-shRNA, the entire LTRhsp-shRNA along with the minimal polyA signal sequence was PCR amplified and cloned in Not I and BstE II sites of pHIV-7 in the reverse orientation.
- ECR-293 cells were obtained from Invitrogen and maintained according to the supplier's instructions. HT1080 and 293 Cells were maintained in DMEM 20% FBS. Twenty-four hours before transfection, cells were replated in 6-well plates at 50-70% confluency with fresh medium without antibiotics. The Human T cell Line CEM was maintained in RPMI1640 medium supplemented with 10% FBS. For co-transfection, the target (either pIND RevEGFP or pNL4-3) was used in a 1:2 weight/weight ratio with the shRNA constructs and transfection was carried out using Lipofectamine Plus (GibcoBRL) according to the manufacturer's instructions. For induction of the rev-EGFP or shRNA construct, 5 M ponasterone A (Invitrogen) was added to the cell culture. Two days post induction, the transfected cells were visualized by fluorescent microscopy. Images were collected using an Olympus BX50 microscope and DEI-750 video camera (Optronics) at 40× magnification with an exposure time of ¼ sec. Specific silencing of target genes was confirmed in at least three independent experiments.
- Total RNA was extracted using RNA STAT-60 (TEL-TEST “B”) according to the manufacturer's instructions. 15 μg of total RNA was electrophoresed in a 10% polyacrylamide/8M urea gel. RNA was transferred by electroblotting onto a Hybond-N+ membrane (Amersham Pharmacia Biotech). The hybridization was performed using an oligonucleotide probe complementary to the antisense strand of the siRNA. Hybridizations were carried out at 37° C. and the filters were washed twice with 2×SSPE at 39° C. and then once with 1×SSPE at 41° C. prior to autoradiographic exposure.
- 293T cells were cultured until they reached 80% confluency in a 100 mm culture dish. 15 ng of lentiviral vector with the appropriate insert, 15 μg of pCHGP-2, 5 μg of pCMV-G and 5 μg of pCMV-Rev were cotransfected into 293T cells using the calcium phosphate precipitation procedure (Graham and van der Eb, 1973). The packaging system is shown in
FIG. 3A (Gasmi et al., 1999). Six hours after transfection, the culture medium was replaced. The culture supernatants were collected at 24 h and 36 h after transfection. The supernatants were pooled together, passed through a 0.45 nm filter, concentrated by ultracentrifugation, and stored at −80° C. until use. Vector titers were determined by transduction of HT1080 cells and assayed for EGFP expression using flow cytometry. The vectors were free of replication competent lentivirus as determined by both RT-PCR and p24 antigen assays. - To transduce CEM T cells, 2×105 cells were placed in a 15 ml centrifuge tube with 1 ml culture medium in the presence of lentiviral vector at a moi of 10.0 and 8 μg/ml polybrene. Following centrifugation at 2000 rpm for 1 h, the cells were transferred into a 24 well culture plate and after 24 h the culture medium was replaced. For transduction of CD34+ cells, CD34+ stem cells were enriched from umbilical cord blood by anti-CD34+ antibody-coupled magnetic beads (Miltenyi Biotech, Aubum, Calif.). The purity of CD34+ cells was above 90% as determined by FACS analysis. After overnight culture in Iscove's modified Dulbecco's medium (IMDM) supplemented with 20% FBS, IL-3 (10 ng/ml), IL-6 (10 ng/ml) and SCF (10 ng/ml) in fibronectin-treated plates, the cells were transduced with lentiviral vectors at a moi of 40.
- Twenty-four hours after transduction, 1×106 CEM-T cells were infected with HIV-1 strain IIIB at a moi of 0.005. After overnight incubation, the cells were washed three times with Hanks' balanced salts solution (HBSS) and cultured in medium with R10 (RPMI 1640+10% FBS) for CEM-T cells. At designated days, cell culture supernatant was collected for HIV-1 p24 antigen analysis. For challenges of CD34 stem cells, lentiviral vector-transduced CD34+ cells were propagated in IMDM containing 20% FBS, IL-3 (10 ng/ml), IL-6 (10 ng/ml), and SCF (10 ng/ml) on irradiated human stroma cells for one week. 2×105 CD34+ cells were exposed to JR-FL strain of HIV-1 at a moi of 0.01 overnight. The infected cells were washed four times with HBSS and the cultures were continued in the medium containing the cytokines. At designated days, cell culture supernatant was collected for HIV-1 p24 antigen analysis.
- Cells were co-transfected with HIV-1 proviral DNA pNL4-3 and the appropriate shRNA constructs. Culture supernatants were collected at twenty-four hour intervals and analyzed for HIV-1 p24 antigen using an ELISA assay (Beckman Coulter Corp). The p24 values were calculated using a Dynatech MR5000 ELISA plate reader (Dynatech Lab Inc). Cell viability was also performed using a Trypan blue dye exclusion count 4 days post transfection.
- To demonstrate expression of shRNA from a Pol II promoter, an shRNA consisting of a 28 base pair stem with a 9 base loop specifically targeted to HIV-1 rev was inserted downstream of the ponasterone A inducible promoter (pIND) in two different Pol II expression cassettes, with or without the 5′ leader element of the minimal hsp70 promoter from the pIND vector (
FIG. 1A ). A minimal polyA sequence was included as previously described (Xia et al., 2002). According to one publication, the 5′ hsp leader element is essential for the transcriptional elongation block observed with the Drosophila hsp70 promoter (Lee et al., 1992). It was therefore assumed that removal of the leader sequence from the transcripts would allow functional shRNA expression, but would eliminate the inducibility of the system. It was further assumed that the complete pIND construct would be inducible by ponasterone A but would contain a long leader sequence which would have to be processed to produce a functional sh/siRNA. Since the shRNA contains a stem of 28 base pairs, it was possible that the entire transcript would be a Dicer substrate, thereby making siRNA production inducible. - In order to assay the siRNAs, the HIV-1 Rev gene was fused to EGFP and expressed in the pIND vector system. EGFP fluorescence was observed as early as 3 hours post addition of the inducer ponasterone A and continued for more than 100 hours. EcR-293 cells were co-transfected with the various shRNA expression constructs and pIND-REV-EGFP. EcR-293 cells are modified HEK 293 cells that stably express the ecdysone receptor and are inducible by the ecdysone analog ponasterone A. Sixteen to twenty hours post transfection, ponasterone A was added to induce the expression of both the shRNA constructs as well as the target rev-EGFP RNA. The cells were incubated for an additional 48 hours prior to fluorescent microscopic analysis. As seen in
FIG. 1B , the shRNA construct lacking the leader element resulted in pronounced inhibition of the EGFP signal relative to the control construct. In contrast, the shRNA construct harboring the hsp70 leader gave no inhibition. Cells transfected with an irrelevant shRNA construct also showed no inhibition of Rev-EGFP. - To determine whether or not the shRNA was being expressed and processed to siRNA-sized products, ECR-293 cells were transfected with the various shRNA constructs. Seventy-two hours post-transfection, RNAs were isolated from cells either treated or untreated with the inducer ponasterone A and Northern gel analyses were carried out. The mpIND-shRNAmpolyA construct lacking the hsp leader element, whether grown in the presence or absence of ponasterone A, resulted in readily detectable RNAs of the size expected from partially processed and fully processed shRNAs (
FIG. 1C ). The construct in which the leader element was retained showed inducible expression of a long, unprocessed RNA precursor, but no siRNA sized products. This would be expected as Drosophila hsp70 transcription is controlled by proximal promoter pausing where elements both upstream and downstream of the TATA box play a role. Deletions downstream of the TATA box would abolish pausing which however can be restored by duplicating a sequence upstream of the hsp70 TATA box (Lee et al., 1992). - Functional inhibition of HIV-1 in transient co-transfection assays by the shRNA constructs was demonstrated by co-transfecting ECR-293 cells with HIV-1 pNL4-3 proviral DNA and mpIND-shRNAmpolyA in the presence or absence of ponasterone A. Culture supernatants were collected and ELISAs for HIV-1 p24, a reliable indicator of HIV infection, were carried out. Cells transfected with mpIND-shRNAmpolyA resulted in about 2 logs of inhibition of HIV-1 p24 expression relative to the control vector. Addition of the inducer ponasterone A did not enhance the anti-HIV-1 activity to any significant extent (
FIG. 1D ). Northern gel analyses of these cells showed that the shRNA was readily detectable and processed to siRNA-sized products both in the presence and absence of ponasterone A (FIG. 1E ). - A number of studies with RNA based antivirals have shown that ribozymes and antisense RNA when expressed from the HIV LTR can efficiently inhibit viral replication in cells infected with HIV (Dropulic et al., 1996; Paik et al., 1997). The expression depends on the presence of the viral transactivator protein TAT which binds to the TAR loop and recruits P-TEFb (P-transcription elongation factor b), a heterodimer of CDK9 and cyclinT1, which in turn phosphorylates the CTD of RNA polymerase and makes it elongation competent (Karn, 1999; Kabor and Greenblatt, 2002). However, it has been previously demonstrated (Xia et al., 2002) and confirmed that shRNAs with appended, non-target derived 5′ extensions do not function effectively in RNAi.
- To circumvent this problem, an expression strategy was devised that results in the first base of the transcript being the first base of the shRNA. This approach exploits the striking similarities reported between the Drosophila hsp70 promoter and the HIV-1 LTR and the fact that the hsp70 core promoter is receptive to a variety of activators (Brand and Perrimon, 1993; No et al., 1996). Both of these promoters show significant similarities in the region flanking their TATA boxes and both the promoters are regulated by promoter proximal pausing which can be relieved by P-TEFb kinase (Krumm et al., 1993). Both the HIV-1 LTR and hsp70 promoter show similar kinetics when activated with heat shock (Kretz-Remy and Arrigo, 1994). It was therefore reasoned that the hsp70 promoter might be regulated by TAT binding to an upstream TAR element.
- In an effort to create an inducible system that would respond to HIV infection, the hsp70 core promoter and the shRNAmpolyA cassette from the mpIND-shRNAmpolyA were inserted downstream of the HIV-1 LTR up to and including the TAR sequences (
FIG. 2A ). It was anticipated that transcription from the HIV-1 LTR might stall following transcription of the TAR loop (Palangat et al, 1998) and immediately upstream of the initiation complex assembled at the downstream hsp70 promoter. It is also known that in the case of both promoters, recruitment of negative transcription elongation factors (N-TEF) consisting of negative elongation factor (NELF) and DRB sensitivity inducing factor (DSIF) suppresses basal transcription (Chwen-Huey et al., 2003; Fujing a et al., 2004). The TAR loop is known to recruit N-TEF, which suppresses transcription from both promoters (Mason and Lis, 1997). HIV-1 TAT bound to the TAR element upstream of the hsp70 core promoter would recruit P-TEFb, which not only phosphorylates the RD subunit of NELF (Fujinaga et al., 2004) and causes the release of N-TEF, but also in turn could phosphorylate the C terminal domain (CTD) of the RNA polymerase complexed with the hsp70 initiation complex. Phosphorylation of RNAP should relieve this elongation block. The resulting transcript should initiate at position +1 of the shRNA. - To test the above, 293 cells were co-transfected with the LTRhsp-shRNA construct in the presence and absence of a plasmid expressing TAT fused to dsRedl. 72 hours post transfection, the cells were visualized by fluorescence microscopy. Fluorescent microscopic examination of these cells revealed about 80% transfection efficiency showing that TATdsRed was efficiently expressed in transfected cells (data not shown). Northern blot analyses of the transfected cells shows that the shRNA was expressed and processed to siRNA-sized products only in the presence of TATdsRed1 (
FIG. 2B ). To verify that transcription from the hsp70 core promoter and not the HIV-1 LTR resulted in expression of the active siRNA-sized products, a construct was created and tested in which the hsp70 TATA box was mutated to an inactive form. When the vector harboring this promoter was tested for shRNA expression, no shRNA or siRNA-sized products were detected in the presence and absence of Tat. These results demonstrate that transcription preferably be initiated from the hsp70 TATA box in order to be functionally processed into an siRNA. Transcripts originating from the HIV-1 LTR would have an additional TAR loop at the 5′ end of the sense strand which would impede recognition and processing to siRNAs. - To better estimate the extent to which the LTRhsp-shRNA was effective against HIV replication, pNL4-3 proviral DNA was transiently co-transfected with the various shRNA constructs into HEK 293 cells. HIV replication was assessed by ELISAs for HIV-encoded p24 in culture supernatants. As can be seen from
FIG. 2C , there was an approximate 90% inhibition of HIV-1 gene expression mediated by the LTRhsp-shRNA construct relative to cells transfected with pNL4-3 and irrelevant siRNA, which is comparable to the inhibition observed with the shRNA expressed from mpIND-shRNAmpolyA construct. The hsp70 TATA mutant failed to show any inhibition. Northern blot analyses of the RNAs from these transfections showed that the shRNA/siRNA was induced in the presence of HIV-1 pNL4-3 (FIG. 2D ). This result demonstrates HIV-1 infection is sufficient to induce shRNA expression from the LTRhsp-shRNA construct. In this setting, expression of TAT functions as part of a negative feedback loop that results in transcriptional activation of the anti-rev siRNA. The negative control for these experiments is the mutant hsp70 TATA box construct from which no detectable shRNA/siRNAs were produced. - According to one report, the HIV-1 TATA box is constitutively bound by the TATA binding protein (TBP) and TBP-associated factors (TAFs) (Mason and Lis, 1997). This binding might serve as a ‘roadblock’ to transcription originating from the HIV-1 LTR and would cause arrest or at least a decrease in productive transcription from the HIV-1 LTR. To test if this was so and whether the hsp70 initiation complex served as a transcription roadblock, 293 cells were co-transfected with pNL4-3 and the LTRhsp-shRNA or hsp70 TATA mutant construct. Total RNA was extracted and RT-PCR analysis was carried out using a 5′ primer complementary to the TAR loop and a 3′ primer designed to hybridize with the sequence between the hsp70 TATA box and shRNA transcription start. If the TAFs at the hsp70 TATA served as a ‘roadblock’ to transcription from the HIV LTR, there would be a decrease in the RT-PCR signal relative to the signal obtained using RNA from the hsp70 TATA mutant construct. As seen in
FIG. 4 , both lanes gave a similar RT-PCR signal after compensating for the internal standard GAPDH signal. - Thus, this data does not support a ‘roadblock’ model as suggested for some genes regulated by dual promoters or TATA boxes. In those situations, the majority of the transcripts originate from the downstream promoter such as has been reported for the human fatty acid synthase gene (Hsu et al., 1996). This data supports a model wherein the hsp70 initiation complex is phosphorylated as a ‘bystander’ due to the P-TEFb, which is recruited in close proximity by the TAT-TAR interaction. It has been shown that a strong transcription pause delays human RNAPII at the base of the TAR loop (position +62) (Palangat et al., 1998). This pause is independent of the promoter proximal pausing and would occur even in presence of TAT. The pause, with a half-life of about 22 seconds, is due to the formation of a hairpin structure which causes the RNAP to reverse translocate by 2 nucleotides. This allows time for the assembly of the initiation complex at the downstream hsp70 promoter. This pausing is important to the system as attempts to abolish the pausing by activating transcription from the HIV-1 LTR via the NF-κB pathway reduced transcription from the hsp70 promoter by a factor of 2 (data not shown).
- In a preferred embodiment, the short hairpin RNA expressed from the various promoters consists of two 28 base arms separated by a 9 base loop sequence. Thus, an shRNA that is processed fully from the 3′ end should result in a transcript that is ˜65 bases in length. When the probe used was complementary to the antisense strand, the partially processed hairpin seen in
FIG. 5A , was determined to be ˜39-40 bases. This product was not detectable when a probe complementary to the sense strand was used, suggesting a partial processing of some shRNA molecules in which a cleavage eliminates the sense strand, leaving behind the antisense plus all or most of the loop (FIG. 5B ). This intermediate appears to accumulate to relatively high levels relative to the fully processed siRNAs. At this time it is not known if the partially processed shRNA is a dead end product or an siRNA precursor. - To show that the present invention is useful in a more stable gene therapy setting, the LTRhsp-shRNA construct was cloned in pHIV-7 in the reverse orientation. When 293 cells were co-transfected with pNL4-3 and LTRhsp-shRNA in pHIV-7, HIV inducible siRNA expression was observed from this construct in a transient transfection assay (data not shown). Primary CD34+ hematopoietic stem cells and CEM T cells were transduced with the LTRhsp-shRNA construct cloned in pHIV-7. The transduced cells were infected with HIV-1 JRFL or HIV-1 IIIB, respectively, at an MOI of 0.005. Culture supernatants were collected at different time points and analyzed for p24 levels by ELISA. As seen in
FIGS. 3B and 3C , 85% and 92% inhibition of p24 levels were observed in CEM T cells and CD34 stem cells, respectively, transduced with pHIV-LTRhsp-shRNA as compared to vector backbone transduced cells. - The fusion promoter of the present invention is believed to be the first report of an HIV-1 inducible siRNA system. Earlier studies have shown that TAT can transactivate heterologous promoters when the TAR element is placed downstream of the promoter (Han et al., 1991). A TAT-GAL4 fusion protein has also been shown to activate transcription from downstream promoter elements when targeted to upstream Ga14 binding sites (Southgate and Green, 1991). The present invention thus is believed to provide the first demonstration of a TAR element upstream of a basal promoter element for activation of transcription from the basal promoter. By expressing HIV-1 TAT from an inducible promoter, in one embodiment, the present invention offers a system for inducible expression of a variety of shRNAs, including those to cellular and viral targets. In a preferred embodiment, a cis-regulatory element of viral or cellular origin can be cloned between the TAR element and the hsp70 promoter or downstream of the minimal polyA, as shown in
FIG. 6 . The HIV-1 LTR would still be used to transcribe the TAR loop, whose function would be not as a transcriptional activator by recruiting TAT, but as a repressor by recruiting N-TEF. N-TEF would suppress the transcription from the hsp70 promoter, as was seen in studies of the system of the invention. Additionally, binding of viral specific or tissue specific transcription factors to the cis-regulatory elements inserted in either of the two places above, as shown inFIG. 6 , could phosphorylate the C terminal domain (CTD) of the RNA polymerase complexed with the hsp70 initiation complex. Phosphorylation of RNAP should relieve this elongation block. Using this approach one can use this promoter for inducible expression of siRNA in response to, for example, tissue specific, viral, cellular or engineered transcription factors. For example, in one embodiment, an ecdysone inducible system could be achieved by cloning ecdysone response elements in either of the above places (i.e., between the TAR element and the hsp70 promoter or downstream of the minimal polyA, as shown inFIG. 6 ). - Several studies have focused on inducible Pol III siRNA expression systems (Wiznerowicz and Trono, 2003; Matsukura et al., 2003; van de Wetering et al., 2003) as constitutively expressed siRNAs have to compete with endogenous micro RNAs and also to minimize the possibilities of off-target and interferon effects (Moss and Taylor, 2003; Sledz et al., 2003; Bridge et al., 2003). Since it is unknown what the long term effects of constitutive expression of short hairpin RNAs might have on the micro RNA machinery and the genes these micro RNAs regulate, an inducible system would provide a level of safety that may be required for long term gene therapy treatment of HIV-1 infection in a gene therapy setting. In particular, a drug inducible system, although useful in a research setting, may not be practical in a therapeutic setting, as every cell harboring the siRNA construct would express siRNA on administering the drug. From the perspective of safety in a gene therapy setting, the system of the present invention could be used to activate anti-HIV-1 sh/siRNAs only in cells infected by an active virus thereby eluding potential toxicities that may ensue with long term expression of sh/siRNAs in a therapeutic setting.
- Several studies have focused on the need to use an HIV inducible setting to express their anti-HIV genes (Dropulic et al., 1996; Paik et al., 1997). The fusion promoter system of the invention provides the safety of an HIV-1 inducible system without compromising the efficacy of the antiviral shRNA. Moreover, in a further embodiment the TAT inducible system can be utilized for regulated siRNA production against cellular targets by making the TAT expression system itself inducible.
- The use of the terms “a” and “an” and “the” and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to,”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
- Embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
-
- An, D. et al. (2003). Efficient lentiviral vectors for short hairpin RNA delivery into human cells. Hum Gene Ther 14:1207-1212.
- Berkhout, B. et al. (1989). Tat trans-activates the human immunodeficiency virus through a nascent RNA target. Cell 59:273-282.
- Brand, A. and Perrimon, N. (1993). Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development 118:401-415.
- Bridge, A. et al. (2003). Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 34:263-264.
- Brummelkamp, T. R. et al. (2002). A system for stable expression of short interfering RNAs in mammalian cells. Science 296:550-553 (2002).
- Caplan, N. J. et al. (2001). Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Nall Acad Sci USA 98:9742-9747.
- Chwen-Huey, W. et al. (2003). NELF and DSIF cause promoter proximal pausing on the hsp70 promoter in Drosophila. Genes Dev17:1402-1414.
- Cullen, B. R. (1986). Trans-activation of human immunodeficiency virus occurs via a bimodal mechanism. Cell 46:973-982.
- Dropulic, B. et al. (1996). A conditionally replicating HIV-1 vector interferes with wild-type HIV-1 replication and spread. Proc Natl Acad Sci USA 93:11103-11108.
- Elbashir, S. M. et al. (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494-498.
- Feinberg, M. B. et al. (1991). The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation. Proc Natl Acad Sci USA 88:4045-4049.
- Feng, S. and Holland, S. C. (1988). HIV-1 tat trans-activation requires the loop sequence within tar. Nature 334:165-167.
- Fire, A. et al. (1998). Potent and specific genetic interference by double stranded RNA in Caenorhabditis elegans. Nature 391:806-811.
- Fujinaga, K. et al. (2004). Dyanamics of Human Immunodeficiency Virus transcription: P-TEFb phosphorylates RD and dissociates negative effectors from transactivation response element. Mol. Cell Biol. 24:787-795.
- Gasmi, M. et al. (1999). Requirements for efficient production and transduction of human immunodeficiency virus type 1-based vectors. J. Virol. 73:1828-1834.
- Graham, G. J. and Maio, J. J. (1990). RNA transcripts of the human immunodeficiency virus transactivation response element can inhibit action of the viral trans activator. Proc Natl Acad Sci USA 87:5817-5821.
- Graham, F. and van der Eb A. (1973). A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52:456-467.
- Grishok, A. et al. (2001). Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control C. elegans developmental timing. Cell 106:23-34.
- Han, P. et al. (1991). Transactivation of heterologous promoters by HIV-1 Tat. Nucleic Acids Res 19:7225-7229.
- Hsu, M. et al. (1996). Human fatty acid synthase gene: Evidence for the presence of two promoters and their functional interaction. J Biol Chem 271:13584-13592.
- Hutvagner, G. et al. (2001). A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science. 293:834-838.
- Kao, S. Y. et al. (1987). Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product. Nature 330:489-493.
- Karn, J. (1999). Tackling Tat. J Mol Biol 293:235-254.
- Kennerdell, J. and Carthew, R. (1998). Use of dsRNA-mediated genetic interference to demonstrate that frizzed and frizzled 2 act in the wingless pathway. Cell 95:1017-1026.
- Kobor, M. and Greenblatt, J. (2002). Regulation of transcription elongation by phosphorylation. Biochim Biophys Acta 1577:261-275.
- Kretz-Remy, C. and Arrigo, A. (1994). The kinetics of HIV-1 long terminal repeat transcriptional activation resemble those of hsp70 promoter in heat-shock treated HeLa cells. FEBS Letters 351:191-196.
- Krumm, A. et al. (1993). Common mechanisms for the control of eukaryotic transcriptional elongation. BioEssays 15:659-665.
- Lee H. et al. (1992). DNA sequence requirements for generating paused polymerase at the start of hsp70. Genes Dev 60:284-295.
- Lee, N. S. et al. (2002). Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol 19:500-505.
- Lipardi C. et al. (2001). RNAi as randomly degraded PCR. siRNA primers convert mRNA into dsRNAs that are degraded to generate new siRNAs. Cell 107:297-307.
- Marciniak, R. A. and Sharp, P. A. (1991). HIV-1 Tat protein promotes formation of more-processive elongation complexes. The EMBO Journal 10:4189-4196.
- Mason, P. and Lis, J. (1997). Cooperative and competitive protein interactions at the hsp70 promoter. J Biol Chem 272:33227-33233.
- Matsukura, S. et al. (2003). Establishment of conditional vectors for hairpin siRNA knockdowns. Nucleic Acids Res 31:e77.
- Miyagishi, M. and Taira, K. (2002). U6 promoter-driven siRNAs with four
uridine 3′ overhangs efficiently suppress targeted gene expression in mammalian cells. Nat Biotechnol 19:497-500. - Moss, E. and Taylor, J. (2003). Small-interfering RNAs in the radar of the interferon system. Nat Cell Biol 5:771-772.
- Muesing, M. A. et al. (1987). Regulation of mRNA accumulation by a human immunodeficiency virus trans-activator protein. Cell 48:691-701.
- No, D. et al. (1996). Ecdysone-inducible gene expression in mammalian cells and transgenic mice. Proc Natl Acad Sci USA. 93:3346-3351.
- Okamoto, T. and Wong-Staal, F. (1986). Demonstration of virus-specific transcriptional activator(s) in cells infected with HTLV-III by an in vitro cell-free system. Cell 47:29-35.
- Paik, S. et al. (1997). Defective HIV-1 provirus encoding a multi-target ribozyme inhibits accumulation of spliced and unspliced HIV-1 mRNAs, reduces infectivity of viral progeny, and protects the Cells from pathogenesis. Hum Gene Ther 8:1115-1123.
- Palangat, M. et al. (1998). Transcriptional pausing at +62 of the HIV-1 nascent RNA modulates formation of the TAR RNA structure. Mol Cell 1:1033-1042.
- Rosen, C. A. et al. (1985). The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat. Cell 41:813-823.
- Sijen, T. et al. (2001). On the role of RNA amplification in dsRNA-triggered gene silencing. Cell 107:465-476.
- Sledz, C. et al. (2003). Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 5:834-839.
- Southgate, C. and Green, M. (1991). The HIV-1 tat protein activates transcription from an upstream DNA binding site: implications for tat function. Genes Dev 5:2496-2507.
- van de Wetering, M. et al. (2003). Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector. EMBO Rep 4:609-615.
- Wianny, F. and Zernica-Goetz, M. (2000). Specific interference with gene function by double stranded RNA in early mouse development. Nat Cell Biol 2:70-75.
- Wiznerowicz, M. and Trono, D. (2003). Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J Virol 77:8957-8961.
- Xia, H. et al. (2002). siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 20:1006-1010.
- Yi, R. et al. (2003). Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 17:3011-3016.
Claims (17)
1. An inducible siRNA system for controlling expression of siRNA comprising a promoter operatively associated with an inducible element and an siRNA operably associated with the promoter, wherein siRNA is produced substantially only in the presence of an inducer which is specific for the inducible element.
2. The inducible siRNA system of claim 1 , wherein the siRNA is a short hairpin RNA (shRNA).
3. The inducible siRNA system of claim 1 , wherein the promoter is a Pol II promoter.
4. A cell comprising the inducible siRNA system of claim 1 .
5. The inducible siRNA system of claim 1 , wherein the inducible element is an HIV TAR region, the siRNA encodes a sequence capable of inhibiting HIV replication and the inducer is HIV TAT.
6. The inducible siRNA system of claim 5 , wherein the siRNA is a short hairpin RNA (shRNA).
7. The inducible siRNA system of claim 5 , wherein the promoter is a Pol II promoter.
8. An HIV infected cell in which siRNA expression is induced, comprising an inducible siRNA system according to claim 4 .
9. A method for inhibiting viral replication in an infected cell comprising:
introducing into the cell the inducible siRNA system of claim 1 into the cell in an amount sufficient to inhibit viral replication,
wherein the siRNA encodes a comprising a promoter operatively associated with an inducible element and siRNA encodes a sequence capable of inhibiting viral replication and wherein viral replication is inhibited in the cell by siRNA produced substantially only in the presence of an inducer which is specific for the inducible element.
10. The method of claim 9 , wherein the siRNA is a short hairpin RNA (shRNA).
11. The method of claim 9 , wherein the virus is HIV, the inducible element is the HIV TAR region and the inducer is HIV TAT.
12. The method of claim 9 , wherein the promoter is a Pol II promoter.
13. The method of claim 9 , wherein the cell further comprises the inducer.
14. A method for reducing expression of a target gene in a cell comprising:
introducing the inducible siRNA system of claim 1 into the cell in an amount sufficient to reduce expression of the target gene,
wherein the siRNA encodes a sequence that is capable of reducing expression of the target gene and wherein target gene expression is reduced in the cell by siRNA produced substantially only in the presence of an inducer which is specific for the inducible element.
15. The method of claim 14 , wherein the siRNA is a short hairpin RNA (shRNA).
16. The method of claim 14 , wherein the promoter is a Pol II promoter.
17. The method of claim 14 , wherein the cell further comprises the inducer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/425,065 US20120238022A1 (en) | 2004-11-23 | 2012-03-20 | INDUCIBLE SYSTEMS AND METHODS FOR CONTROLLING siRNA EXPRESSION |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62989004P | 2004-11-23 | 2004-11-23 | |
US11/283,410 US8138327B2 (en) | 2004-11-23 | 2005-11-21 | Inducible systems and methods for controlling siRNA expression |
US13/425,065 US20120238022A1 (en) | 2004-11-23 | 2012-03-20 | INDUCIBLE SYSTEMS AND METHODS FOR CONTROLLING siRNA EXPRESSION |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/283,410 Continuation US8138327B2 (en) | 2004-11-23 | 2005-11-21 | Inducible systems and methods for controlling siRNA expression |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120238022A1 true US20120238022A1 (en) | 2012-09-20 |
Family
ID=36575120
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/283,410 Active US8138327B2 (en) | 2004-11-23 | 2005-11-21 | Inducible systems and methods for controlling siRNA expression |
US13/425,065 Abandoned US20120238022A1 (en) | 2004-11-23 | 2012-03-20 | INDUCIBLE SYSTEMS AND METHODS FOR CONTROLLING siRNA EXPRESSION |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/283,410 Active US8138327B2 (en) | 2004-11-23 | 2005-11-21 | Inducible systems and methods for controlling siRNA expression |
Country Status (1)
Country | Link |
---|---|
US (2) | US8138327B2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010062941A1 (en) * | 2008-11-26 | 2010-06-03 | University Of Kansas | Nucleic acid delivery compositions and methods |
EP2481804A1 (en) | 2011-01-31 | 2012-08-01 | Heinrich-Pette-Institut Leibniz-Institut für experimentelle Virologie-Stiftung bürgerlichen Rechts - | Lentiviral vector comprising at least two TAR elements |
US20140037599A1 (en) * | 2012-08-03 | 2014-02-06 | The Trustees Of The University Of Pennsylvania | Compositions and Methods of Treating T Cell Deficiency |
CN105018528B (en) * | 2015-08-20 | 2018-04-03 | 重庆大学 | Heat shock protein gene promoter and the multi-gene expression and silencing system of the control of tetracycline gene promoter |
US20180230489A1 (en) | 2015-10-28 | 2018-08-16 | Voyager Therapeutics, Inc. | Regulatable expression using adeno-associated virus (aav) |
KR20230110812A (en) | 2017-10-10 | 2023-07-25 | 난트바이오 인코포레이티드 | Modified ec7 cells having low toxicity to viral production payloads |
US11643672B2 (en) | 2021-10-01 | 2023-05-09 | The Florida International University Board Of Trusters | Inducible CRISPR system expression and applications thereof |
CN114277030A (en) * | 2021-12-28 | 2022-04-05 | 滨州医学院 | pri-miRNA (pri-microribonucleic acid) modified sequence and vector for expressing sequence |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030203868A1 (en) * | 2002-02-06 | 2003-10-30 | Bushman Frederic D. | Inhibition of pathogen replication by RNA interference |
US20040018176A1 (en) * | 2002-07-24 | 2004-01-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for siRNA inhibition of angiogenesis |
US20040023390A1 (en) * | 2002-08-05 | 2004-02-05 | Davidson Beverly L. | SiRNA-mediated gene silencing with viral vectors |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1354038A2 (en) * | 2000-12-28 | 2003-10-22 | J & J Research Pty Ltd | Double-stranded rna-mediated gene suppression |
US20030170891A1 (en) * | 2001-06-06 | 2003-09-11 | Mcswiggen James A. | RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US7919309B2 (en) * | 2001-09-13 | 2011-04-05 | California Institute Of Technology | Method for expression of small antiviral RNA molecules within a cell |
WO2003046173A1 (en) * | 2001-11-28 | 2003-06-05 | Center For Advanced Science And Technology Incubation, Ltd. | siRNA EXPRESSION SYSTEM AND PROCESS FOR PRODUCING FUNCTIONAL GENE-KNOCKDOWN CELLS AND THE LIKE USING THE SAME |
EP1572956A2 (en) * | 2002-08-01 | 2005-09-14 | City of Hope | Methods and kits for synthesis of sirna expression cassettes |
CA2497892A1 (en) * | 2002-09-04 | 2004-03-18 | Provost, Fellows And Scholars Of The College Of The Holy And Undivided T Rinity Of Queen Elizabeth Near Dublin | Compositions and methods for tissue specific or inducible inhibition of gene expression |
AU2003279010A1 (en) * | 2002-09-28 | 2004-04-19 | Massachusetts Institute Of Technology | Compositions and methods for delivery of short interfering rna and short hairpin rna |
-
2005
- 2005-11-21 US US11/283,410 patent/US8138327B2/en active Active
-
2012
- 2012-03-20 US US13/425,065 patent/US20120238022A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030203868A1 (en) * | 2002-02-06 | 2003-10-30 | Bushman Frederic D. | Inhibition of pathogen replication by RNA interference |
US20040018176A1 (en) * | 2002-07-24 | 2004-01-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for siRNA inhibition of angiogenesis |
US20040023390A1 (en) * | 2002-08-05 | 2004-02-05 | Davidson Beverly L. | SiRNA-mediated gene silencing with viral vectors |
Non-Patent Citations (2)
Title |
---|
Czauderna et al., Inducible shRNA expression for application in a prostate cancer mouse model, 2003, Nucleic Acids Research, volume 31, e127, pages 1-7. * |
Gupta et al., Inducible, reversible, and stable RNA inteference in mammalian cells, 2004, PNAS, volume 101, pages 1927-1932. * |
Also Published As
Publication number | Publication date |
---|---|
US20060122139A1 (en) | 2006-06-08 |
US8138327B2 (en) | 2012-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20120238022A1 (en) | INDUCIBLE SYSTEMS AND METHODS FOR CONTROLLING siRNA EXPRESSION | |
Ter Brake et al. | Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition | |
Unwalla et al. | Negative feedback inhibition of HIV-1 by TAT-inducible expression of siRNA | |
US20070081982A1 (en) | Multiple RNAi expression cassettes for simultaneous delivery of RNAi agents related to heterozygotic expression patterns | |
Morris et al. | Lentiviral-mediated delivery of siRNAs for antiviral therapy | |
US7195916B2 (en) | Method for expression of small antiviral RNA molecules within a cell | |
KR100774041B1 (en) | Small interference rna gene therapy | |
Westerhout et al. | The virion-associated incoming HIV-1 RNA genome is not targeted by RNA interference | |
JP2005521393A (en) | HIV treatment | |
JP2004532616A (en) | Double-stranded RNA-mediated gene suppression | |
EP1799824A2 (en) | Nucleic acids against viruses, in particular hiv | |
Saayman et al. | The efficacy of generating three independent anti-HIV-1 siRNAs from a single U6 RNA Pol III-expressed long hairpin RNA | |
Janas et al. | Lentiviral delivery of RNAi in hippocampal neurons | |
Barichievy et al. | The inhibitory efficacy of RNA POL III-expressed long hairpin RNAs targeted to untranslated regions of the HIV-1 5′ long terminal repeat | |
JP4536112B2 (en) | New method to overcome RNAi resistant virus strains | |
US11643672B2 (en) | Inducible CRISPR system expression and applications thereof | |
Katare et al. | Rna based therapeutics | |
Barichievy | Post-transcriptional inhibition of human immunodeficiency virus type 1 (HIV-1) using combinatorial RNA interference (RNAi) expression vectors | |
McIntyre | Antiviral shRNA (for HIV-1) | |
Park | Anti-HIV RNAs and Viral Vectors for Gene Therapy | |
Singer et al. | 12 siRNA delivery by lentiviral vectors: Design and applications | |
Newton | Production of self-inactivating lentiviral vectors to establish transgenic fetal equine kidney cell lines | |
An et al. | Lentiviral vector mediated delivery of si/shRNA | |
Saayman | Inhibiting HIV-1 Gene Expression and Replication with Expressed Long Hairpin RNAs | |
Turner et al. | Transcriptional gene silencing as a genetic therapy for HIV-1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |